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Abstract 
 
Abdominal pain places a large burden on society and its current management is sub-
optimal due to the lack of visceral-specific analgesics. Voltage-gated sodium 
channels (Nav) are crucial for action potential generation and Nav1.9 has the lowest 
activation threshold of all these channels. In addition, Nav1.9 expresses a unique, 
slow, persistent current and is peripherally expressed on small diameter dorsal root 
ganglion (DRG) neurons. Whereas, at the level of the DRG, the Nav1.9 current is 
enhanced in response to a number of inflammatory mediators, no data exist for the 
role of Nav1.9 in signalling at the nerve terminal. Behavioural studies in mice have 
established a role for Nav1.9 in the response of somatic afferents to inflammatory 
mediators where it has a role in the immediate response of the afferents as well as 
in the development of hyperalgesia. No studies have investigated the role of Nav1.9 
in the response of visceral afferents to inflammatory and mechanical stimuli.  
 
This thesis investigated the role of Nav1.9 in the response of visceral afferents to a 
variety of chemical and mechanical stimuli. Electrophysiological recording of colonic 
and intestinal afferents from Nav1.9 wild type and knockout mice were made using a 
bespoke recording chamber. The tissue was superfused with a number of chemical 
mediators and the change in peak afferent activity compared between wild type and 
knockout mice. For some experiments, human inflammatory supernatant was 
generated from inflamed and control appendices. The effect of this supernatant on 
visceral afferents and the role of Nav1.9 in this response were studied. The response 
of visceral afferents to intraluminal distension was also studied in Nav1.9 wild type 
and knockout mice.  
 
The data presented in this thesis demonstrate a pivotal role for Nav1.9 in the 
activation of visceral afferents by chemical and mechanical stimuli as well as a 
human inflammatory supernatant. The response of colonic and intestinal afferents 
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to bradykinin, capsaicin and intraluminal distension is significantly attenuated in 
Nav1.9 knockout mice. Although the peak response of afferents to acetic acid was 
not significantly different between the genotypes, there were significant differences 
in the profile of the responses. Additionally, the data show that cyclooxygenase 
blockade enhances the effect of elimination of Nav1.9 on the response of afferents 
to noxious stimuli. Finally, the activation of visceral afferents by human 
inflammatory supernatants was significantly decreased in Nav1.9 knockout mice 
suggesting that blockade of this channel in man could provide analgesic effects that, 
due to its restricted peripheral distribution, would not be expected to be associated 
with the side effect profile of the current non-specific sodium channel blockers.  
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1  
Introduction 
 
1.1 Abdominal pain 
 
1.1.1 Burden of abdominal pain 
The International Association for the Study of Pain (IASP) defines pain as “an 
unpleasant sensory and emotional experience associated with actual or potential 
tissue damage” (IASP 2011). It is clear from this definition that there are two 
elements to feeling pain: the actual stimulation of nerve endings and the 
psychological element that often influences how a person reacts to the stimulus. 
Acute abdominal pain is one of the three most common presentations to emergency 
departments, with 7 million presentations in the United States in 2007-8 (Bhuiya et 
al. 2010). There are three main causes of pain: inflammation of an organ, e.g. 
appendicitis or inflammatory bowel disease (IBD), occlusion of flow causing 
distension, e.g. ureteric stones or an obstructing tumour, or functional disorders, e.g. 
irritable bowel syndrome (IBS) or non-ulcer dyspepsia. Although the vast majority of 
episodes resolve either spontaneously or after medical management, the prevalence 
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of chronic abdominal pain is estimated at 25% (Halder and Locke 2009). Pain, both 
acute and chronic, places a large burden on health and social care systems with the 
cost of functional digestive diseases estimated at over $40 billion in 8 major 
industrialised countries (Fullerton 1998). Only 25% of this is in the form of direct 
healthcare costs, while the majority relates to indirect costs incurred from loss of 
productivity (Fullerton 1998).  
 
1.1.2 Treatment of abdominal pain 
In patients where the cause of abdominal pain is established, medical or surgical 
management of the underlying condition usually results in resolution of the pain, e.g. 
appendicectomy for appendicitis or antibiotics followed by cholecystectomy for 
cholecystitis. In addition to the medical treatment, patients are often prescribed 
analgesics that have differing modes of action, e.g. paracetamol, non-steroidal anti-
inflammatory drugs (NSAIDs), anti-spasmodics and opioids. Although a combination 
of these drugs usually provides adequate analgesia, this is complicated by their side 
effect profiles, e.g. nausea or constipation. In addition, surveys have shown that only 
10-30% of patients seek medical advice for chronic pain (Fullerton 1998; Halder et al. 
2002; Halder and Locke 2009) with the majority accepting chronic pain as part of 
daily life (Halder and Locke 2009).  
 
A recent survey of IBD patients conducted by the National Association for Colitis and 
Crohn’s Disease (NACC) revealed that 61% of patients experienced abdominal pain 
during remission, with three quarters ranking their pain as 5 or greater on a 1-10 
scale (NACC 2008). Of the patients who approached a medical practitioner, 68% 
were prescribed analgesia (commonly paracetamol, NSAIDs, anti-spasmodics or 
tramadol), which provided a degree of relief in only 70% of patients (NACC 2008). 
The survey findings demonstrated that over 50% of those who approached a medical 
practitioner for management of their abdominal pain did not get adequate relief. 
This correlates with a large pan-European survey which revealed that 40% of people 
with chronic pain of various types had inadequate management of their pain (Breivik 
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et al. 2006). Inadequate pain control interferes with a person’s ability to carry out 
activities of daily living including going to work, maintaining relationships and 
enjoying hobbies. In addition, patients may experience anxiety, fear, anger and 
depression (Becker et al. 1997). The consequent deterioration in their quality of life 
can prompt them to consider the extreme measure of suicide as their only coping 
strategy (Hitchcock et al. 1994). These surveys highlight the current poor pain 
management of patients who have both life-long inflammatory conditions and 
functional gastrointestinal (GI) diseases and illustrate the need for the development 
of visceral specific analgesics which will have more favourable side effect profiles. 
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1.2 Nociception in the gastrointestinal tract 
 
Chronic abdominal pain is associated with distorted signalling of visceral afferents. 
Our understanding of this signalling is derived from experiments in animals and the 
following description relates mainly to experiments in rodents. While it is likely that 
the innervation is representative of that in man, there is a paucity of studies that 
have investigated the extrinsic innervation of the human GI tract.  
 
1.2.1 Anatomy of visceral afferents 
The GI tract is served by both intrinsic and extrinsic nerves. Anatomically, the 
extrinsic nerves are made up of vagal and spinal nerves with the spinal nerves 
further subdivided into splanchnic and pelvic populations. The vagus nerve 
innervates the GI tract down to the transverse colon (Berthoud and Neuhuber 2000) 
while spinal afferents innervate the whole of the GI tract (Christianson and Davies 
2010) (Figure 1). The majority of extrinsic afferents are unmyelinated C fibres with a 
minority of thinly-myelinated A delta (Aδ) fibres (Prechtl and Powley 1990; Sengupta 
and Gebhart 1994; Robinson et al. 2004; Tan et al. 2009). These afferents have 
unencapsulated nerve endings in all layers of the gut wall with subspecialisation of 
function dependent on the location of the afferent terminal as well as the receptors 
and ion channels expressed on the terminal (Figure 2). 
 
1.2.1.1 Vagal afferents 
Vagal afferents have their cell bodies in nodose ganglia (NG) and terminate in the 
nucleus tractus solitaries. Vagal afferents have 3 distinct terminals that exist in 
specific locations within the gut wall: intramuscular arrays (IMAs) within longitudinal 
and circular muscle layers especially in the stomach (Berthoud and Powley 1992), 
intraganglionic laminar endings (IGLEs) which form basket-like structures 
surrounding myenteric ganglia (Berthoud et al. 1997; Zagorodnyuk and Brookes 
2000) and mucosal endings in the lamina propria in close proximity to the mucosal 
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epithelium but not exposed directly to the contents of the lumen. The first two 
groups of terminals act as mechanoreceptors within the muscle layers while the 
mucosal afferents have a role in ‘tasting’ the lumen via a number of ‘helper’ cells, 
e.g. enteroendocrine cells (Berthoud and Patterson 1996). These mucosal afferents 
are most abundant in the proximal duodenum (Berthoud and Neuhuber 2000). Due 
to the proximity of IGLEs and myenteric ganglia, there has also been speculation that 
this might be the site of ‘cross-talk’ between the intrinsic and extrinsic systems 
(Grundy 2006).  
 
Figure 1 Visceral afferent pathways in rodents. From oesophagus to proximal colon, the GI tract is 
dually innervated by vagal and spinal afferents in contrast with the lower GI tract which is innervated 
by spinal afferents only. NG - nodose ganglion, CG - coeliac ganglion, SMG/IMG – superior/inferior 
mesenteric ganglion, PG – pelvic ganglion, IMN – intermesenteric nerve, HGN – hypogastric nerve. 1-4 
greater, lesser, least and lumbar splanchnic nerves respectively, 5 pelvic nerve. 
 
1.2.1.2 Spinal afferents 
Spinal afferents have their cell bodies in dorsal root ganglia (DRG) and pass through 
para- and pre-vertebral ganglia to synapse in the dorsal horn, where they converge 
with somatic afferents. It has been established that fewer than 15% of DRG neurons 
are visceral in origin (Neuhuber et al. 1986; Perry and Lawson 1998; Peeters et al. 
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2006). In contrast to somatic afferents that have dense terminations, the visceral 
afferents terminate extensively and thinly in laminae I, V and X of the spinal cord, 
with terminations spread over at least five spinal segments and some crossing into 
contralateral lamina (Sugiura et al. 1989; Knowles and Aziz 2009). The convergence 
of visceral and somatic input explains the phenomenon of referred pain (Bielefeldt 
and Gebhart 2006) while the scattered distribution amongst numerous spinal 
segments may explain the poor localisation of visceral pain by patients (Sugiura et al. 
1989).  
 
 
Figure 2 Nerve endings in the GI tract. From Knowles and Aziz 2009.  
 
The second order neurons project to the brain through the spinomesencephalic, 
spinohypothalamic, spinorecticular and spinothalamic tracts that lie in the 
anterolateral quadrant of the spinal cord. The spinothalamic tract transmits 
conscious somatic and visceral sensation by its projections to the somatosensory 
cortex, anterior cingulate cortex and the insula while the other three tracts mainly 
trigger subconscious responses to the visceral and somatic input (Almeida et al. 
2004; Anand et al. 2007). The transmission of nociception from spinal afferents can 
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be modulated by gating influences from converging viscerosomatic neurons. Visceral 
pain thresholds are increased by viscerosomatic inputs with transient inhibition of 
transmission demonstrated (Tattersall et al. 1986). This may explain the pain relief 
experienced by patients by the application of a hot water bottle to the abdominal 
wall. 
 
A spinal visceral afferent consists of peripheral terminals in the gut wall, a peripheral 
nerve axon, a cell body in the DRG, central axons in the dorsal root and central axon 
terminals in the spinal cord. In rodents, spinal afferents have been shown to consist 
of five classes based on their response to mechanical stimuli: mesenteric, serosal, 
muscular, muscular/mucosal and mucosal (Brierley et al. 2004). Three of these 
classes (serosal, muscular and mucosal) are common to both lumbar splanchnic 
nerve (LSN) and pelvic nerve (PN) afferents but their relative prevalence differs 
between the two populations. Mesenteric afferents are only found in the LSN (where 
they accounted for 50% of all afferents detected) while muscular/mucosal afferents 
are only present on the PN (Brierley et al. 2004). In a study using fast blue to label 
afferents from the descending colon of the mouse, Robinson et al demonstrated 
labelling of DRG from T4 to S3 with two peaks around T8-L1 and L6/S1, which 
represent splanchnic and pelvic populations respectively (Robinson et al. 2004). 
These data are supported by other studies in the mouse and rat that have shown the 
greatest density of labelling of the LSN at T8-T12 and a narrow peak at L6/S1 or L6-S2 
likely to be due to innervation from the PN (Nadelhaft and Booth 1984; Neuhuber et 
al. 1986; Payette et al. 1987). Labelling of gastric afferents has been demonstrated 
between T4 and L2 with a narrow peak at T9/10 (Ozaki and Gebhart 2001) while the 
peak labelling of jejunal afferents is at T12 (Tan et al. 2008). This overlap between 
gastric, jejunal and colonic input into second order neurons explains the poor 
localisation of visceral pain by patients.  
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1.2.2 Signalling of extrinsic visceral afferents 
Most of the information transmitted from the viscera to the central nervous system 
(CNS) is unconsciously processed with the principle conscious sensation being pain. 
Visceral afferents can be classified either anatomically (mucosal/muscular/serosal/ 
mesenteric) or functionally (mechanical/chemical/thermal). Vagal mechanosensitive 
afferents (IMAs and IGLEs) are thought to code mainly within the physiological range 
with a minority that detect noxious gastric distension (Ozaki et al. 
1999). Chemosensitive vagal afferents detect a wide range of luminal stimuli both 
physiological and noxious including acid, cholecystokinin, glucose and fatty acids 
(Berthoud and Neuhuber 2000) using ‘helper cells’ that present mediators to the 
afferent terminal. 
 
Whereas vagal afferents encode mainly within the physiological range, splanchnic 
afferents encode well into the pathological range and are thought to be the main 
pathway for mediating pain perception (Berthoud et al. 2004). Recently, IGLEs have 
been reported in guinea pig rectum which, like the vagal IGLEs, are low threshold, 
slowly adapting receptors (Lynn et al. 2003). These receptors are not seen in 
splanchnic afferents. This suggests that the more focused distribution of vagal and 
pelvic afferents may correspond to areas of the GI tract where graded, innocuous 
sensations can be evoked by distension (Berthoud et al. 2004). 
 
In in vitro recordings, the majority of mechanosensitive spinal afferents have been 
found to be silent at rest (Brierley et al. 2004). In addition, significant differences 
exist in the response of splanchnic and pelvic afferents to mechanical stimuli: 
splanchnic afferents are overall less responsive to mechanical stimulation than pelvic 
afferents and also adapt more completely to mechanical probing. Nearly half of 
pelvic afferents respond to circular stretch or mucosal stroking compared to less 
than 10% of splanchnic afferents (Brierley et al. 2004; Brierley et al. 2005a). Pelvic 
afferents also have lower activation thresholds to electrical stimulation (Feng and 
Gebhart 2011). These characteristics suggest that the pelvic pathway signals 
maintained distension and passage of material whereas the splanchnic pathway 
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signals transient events, e.g. rapid distension or torsion of the mesentery (Brierley et 
al. 2005b).  
 
Mechanosensitivity is influenced by a wide range of mediators released as a 
consequence of inflammation, e.g. bradykinin or prostaglandins, which can reduce 
the activation threshold of afferents leading to hypersensitivity (Kirkup et al. 2001). 
Indeed, some mechanically insensitive afferents develop mechanosensitivity during 
inflammation which may persist after the acute insult (Gebhart 2000). A recent study 
has shown that over a quarter of the afferent population in the distal 3 cm of the 
mouse colon/rectum was mechanically insensitive and that approximately half of 
these acquired mechanical sensitivity after exposure to an inflammatory soup (Feng 
and Gebhart 2011). The study also demonstrated significant differences between 
pelvic and splanchnic afferents: a higher proportion of LSN (33%) than PN (23%) 
afferents was mechanically insensitive but a significantly lower proportion of LSN 
(23%) than PN (71%) gained mechanosensitivity after the inflammatory soup. In 
agreement with results from other in vitro studies, the responses of PN afferents 
were greater than LSN afferents (Feng and Gebhart 2011). An inflammatory soup has 
also been shown to reduce the threshold for, and increase the response to, 
distension of the stomach in vivo (Ozaki and Gebhart 2001). In addition, a role for 
spinal afferents in IBS-related hypersensitivity has been highlighted by a study 
assessing response to mechanical stimuli in mice subjected to trinitrobenzene 
sulfonic acid (TNBS) colitis (Hughes et al. 2009). Splanchnic afferents demonstrated 
increased responses to mechanical stimulation associated with a reduction in the 
activation threshold during the acute and recovery phases. In contrast, pelvic 
afferents only demonstrated these effects in the recovery phase with no change in 
their response during the acute inflammatory phase. The sensitisation of afferents 
was restricted to the high-threshold serosal and mesenteric afferents (Hughes et al. 
2009). Reducing these afferents’ threshold may be the major factor underlying 
hyperalgesia.  
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Spinal afferents also respond directly to application of a number of chemical 
mediators including capsaicin, adenosine-5’-triphosphate (ATP) and bradykinin 
(Brierley et al. 2005a; Brierley et al. 2005b; Song et al. 2009). More splanchnic than 
pelvic afferents respond to these mediators (ATP 40% vs. 7%; capsaicin: 61% vs. 47%; 
bradykinin 66% vs. 11%). Following exposure to capsaicin, splanchnic afferents 
demonstrate desensitisation to mechanical stimuli which is not seen in pelvic 
afferents (Brierley et al. 2005a) while exposure to bradykinin sensitised the 
mechanical response of splanchnic but not pelvic nerves (Brierley et al. 2005b). The 
differential response of afferents to chemical and mechanical stimuli can be 
explained by the differential expression of receptors and ion channels on their 
terminals. Visceral afferents express calcitonin gene-related peptide, Substance P 
and transient receptor potential vanilloid channel (TRPV) 1 and 4 in greater 
proportion than somatic afferents (Perry and Lawson 1998; Robinson et al. 2004; 
Brierley et al. 2008). In addition, DRG neurons express significantly more TRPV1, 
transient receptor potential ankyrin channel (TRPA) 1 and voltage-gated sodium 
channel 1.9 (Nav1.9) than NG neurons (Peeters et al. 2006). More significantly, there 
is a difference in the expression of some receptors amongst spinal visceral afferents, 
with splanchnic afferents expressing significantly more TRPV1 and P2X3 channels 
than pelvic afferents (Brierley et al. 2005a).  
 
1.2.3 Mediators and channels involved in signalling 
Transduction is the conversion of an extracellular stimulus into a generator 
potential. A generator potential is produced by the opening of ion channels in 
response to a depolarising stimulus and is terminated by time, voltage-gated 
inactivation of these channels and the opening of a voltage sensitive outward 
potassium conductance (Glazebrook et al. 2002). When the membrane potential 
exceeds a threshold, an action potential is initiated at the terminal and propagated 
along the axon. The arrival of an action potential at the central terminal results in the 
release of neurotransmitters which bind to receptors on the second order neurons, 
allowing propagation of the signal. There are 3 classes of receptors on afferent 
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terminals: ligand-gated ion channels, voltage-gated ion channels and G-protein 
coupled receptors (GPCRs) (Figure 3).  
 
 
Figure 3 Receptors and mechanisms underlying activation and sensitisation of visceral sensory 
afferents. 5-HT - 5-hydroxytryptamine, ATP - Adenosine-5’-triphosphate, COX – cyclooxygenase, DAG 
– diacylglycerol, IP3 - inositol 1,4,5-triphosphate, PARs - protease activated receptors, PGs – 
Prostaglandins, PKC - protein kinase C, PLA2 - phospholipase A2, PLC - phospholipase C, VR1 - 
Transient receptor potential V1. From Grundy 2002. 
 
Inflammatory mediators are released by numerous cell types in response to tissue 
injury and produce their effects on visceral afferents via three processes: direct 
activation of an ion channel, sensitisation of the afferent through second messenger 
molecules and alteration of the phenotype of the afferent through changes in the 
expression of channels, receptors or other mediators (Kirkup et al. 2001). In addition, 
some receptors share second messenger pathways and hence can be modulated by 
feedback from different mediators (Wood 2000). The major ion channels and 
mediators involved in signalling are discussed further in the following sections.  
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1.2.3.1 Ligand-gated ion channels  
The transient receptor potential (TRP) channel family consists of over 30 members 
grouped into six subfamilies (Wu et al. 2010). They have six transmembrane domains 
and assemble as homo- or hetero-tetramers to form cation channels that allow 
calcium into the cells when activated. A number of TRP channels have been 
implicated in nociception.  
 
TRPV1 is the receptor for capsaicin, protons and temperatures over 43 ˚C (Caterina 
et al. 1997). It is preferentially located on small to medium diameter neurons 
(Caterina et al. 2000) and modulated by protein kinase C (PKC) (Premkumar and 
Ahern 2000; Vellani et al. 2001; Numazaki et al. 2002). TRPV1 expression is increased 
in colorectal tissue from patients with an acute exacerbation of their IBD (Yiangou et 
al. 2001b) or rectal hypersensitivity (Chan et al. 2003; Akbar et al. 2008) while TRPV1 
-/- mice lack the afferent hypersensitivity associated with inflammation (Caterina et 
al. 2000; Davis et al. 2000; Jones et al. 2005). In addition, DRG of adult mice that 
were subjected to acetic acid infusion as neonates revealed significant increase in 
TRPV1 expression (Winston et al. 2007). In vivo studies of colorectal distension in 
rats have demonstrated an important role for TRPV1 in the mechanical 
hypersensitivity of sensitised visceral afferents (Ravnefjord et al. 2009; Vermeulen et 
al. 2013). In addition, a TRPV1 antagonist has been shown to reduce the thermal 
hyperalgesia expressed after injection of complete Freund’s adjuvant (CFA) into the 
hind paw of rats (Joshi et al. 2009). These studies highlight a significant role for 
TRPV1 in the sensitisation of visceral and somatic afferents.  
 
TRPV4 is an osmo-sensitive channel that responds to mechanical stimulation and 
temperatures between 27 and 34 ˚C (Wu et al. 2010). It is postulated to play a 
significant role in mechanical transduction in the gut. Colonic instillation of a TRPV4 
agonist provokes allodynia and hyperalgesia to colonic distension in mice and this 
was reduced in mice injected with small interfering ribonucleic acid (siRNA) to TRPV4 
(Cenac et al. 2008). In agreement with the above, knock out of TRPV4 causes an 
George Boundouki 
 
 
 31 
increased threshold to mechanical stimulation and a reduction in the response to 
von Frey probing in vitro and balloon distension of the distal colon in vivo (Brierley et 
al. 2008). Tissue from patients suffering from an acute exacerbation of their IBD 
demonstrates increased labelling for TRPV4 (Brierley et al. 2008). 
 
TRPA1 is the receptor for mustard and cinnamon as well as temperatures below 17 
˚C (Story et al. 2003; Wu et al. 2010) and is co-expressed with TRPV1 (Story et al. 
2003; Kobayashi et al. 2005). In addition, TRPA1 has been shown to play an 
important role in the responses to balloon distension of the mouse colon and rat 
stomach (Brierley et al. 2009; Kondo et al. 2009). This has been corroborated by in 
vitro studies demonstrating a reduced response and increased threshold to 
mechanical stimulation in TRPA1 -/- mice (Brierley et al. 2009). TRPA1 agonists cause 
significantly greater sensitisation to mechanical stimuli after colonic inflammation 
compared to no inflammation. This effect was absent in TRPA1 -/- mice, highlighting 
a role for TRPA1 in mediating IBD associated hyperalgesia (Brierley et al. 2009).  
 
ATP is released as a result of inflammation, hypoxia, cell acidosis or distension and 
binds to P2X (ligand-gated ion channels) and P2Y (GPCR) receptors to cause an 
inward flow of calcium ions (Bouvier et al. 1991). Of the seven P2X receptors, P2X3 is 
selectively expressed on small diameter sensory neurons (Chen et al. 1995; 
Vulchanova et al. 1998) and P2X3 -/- mice experience attenuated pain behaviours 
(Souslova et al. 2000). Colonic P2X3 expression is increased in IBD in man (Yiangou et 
al. 2001a) and the release of ATP by colorectal distension has been shown to be 
increased in a rat model of colitis, demonstrating a prominent role for ATP in the 
response to inflammation (Wynn et al. 2004).  
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1.2.3.2 Voltage-gated ion channels 
Nerve fibres contain numerous voltage-gated ion channels including potassium, 
calcium and sodium channels. Only those channels involved in membrane 
depolarisation are considered in this section. 
 
Voltage-gated calcium channels comprise of an α1 channel-forming subunit 
associated with α2δ, β and γ subunits. Each α1 subunit comprises of four repeat 
domains of six transmembrane segments (Dolphin 2012). Activation of voltage-gated 
calcium channels alters the membrane potential and contributes to the excitability 
of sensory neurons. These channels also play a crucial role in neurotransmitter 
release from the presynaptic terminals in the dorsal horn.  
 
Voltage-gated sodium channels are transmembrane receptors that are essential for 
the generation of action potentials. They confer excitability on neurons by opening in 
response to membrane depolarisation, thus allowing influx of sodium ions. Because 
of the direct relevance of these channels to the thesis, they are discussed separately 
in section 1.3 below. 
 
1.2.3.3 G-protein coupled receptors 
GPCRs are the largest family of cell surface mediators of signal transduction with 
approximately 800 human genes coding for functional GPCRs. They share a common 
structure comprising seven α-helical trans-membrane domains connected by 
extracellular and intracellular loops. They interact with G-proteins which then 
modulate the activity of a number of effectors, e.g. phospholipases and ion channels 
(Neer 1995). Only the most relevant substrates of GPCRs are discussed here.  
 
A major aspect of the inflammatory response is the direct release of cytokines, e.g. 
Interleukin (IL) -1β, IL-8 and Tumour necrosis factor alpha (TNFα), and the 
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recruitment of leukocytes that causes further release of cytokines. Cytokines are low 
molecular weight regulatory proteins that commonly stimulate the release of other 
mediators and cause phosphorylation of ion channels, leading to sensitisation of 
afferents (Kidd and Urban 2001). The inflammatory response is normally resolved by 
the release of anti-inflammatory cytokines (e.g. IL-4, IL-6 and IL-10). An imbalance in 
the proportion of pro- and anti-inflammatory cytokines leads to the development of 
chronic inflammation and associated chronic pain. Studies of peritoneal fluid from 
patients suffering from acute appendicitis or IBD show an elevation in the 
concentrations of IL-1β, IL-6, IL-8 and TNFα amongst others (Rivera-Chavez et al. 
2003; Dalal et al. 2005; Yamamoto et al. 2005) suggesting a role for these cytokines 
in the body’s response to visceral inflammation. 
 
Tissue damage leads to the activation of kallikreins which cleave kininogens to 
generate kinins. Kinins are a group of 9-11 amino acid peptides that include 
bradykinin and its active metabolite, des-Arg9-bradykinin (Couture et al. 2001). 
Bradykinin is an initial mediator of inflammation, induces pain and is a potent 
vasodilator. Its actions are mediated via two GPCRs: bradykinin receptors 1 and 2 (B1 
and B2). B2 is constitutively expressed whereas B1’s expression is induced as a result 
of tissue damage (Couture et al. 2001). Both receptors signal through Gq and activate 
phospholipase C (PLC) which, in turn, cleaves Phosphatidylinositol 4,5-bisphosphate 
(PIP2) into diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP3). DAG activates 
PKC while IP3 leads to the opening of Ca2+ channels and consequent release of Ca2+ 
into the cytoplasm (Leeb-Lundberg et al. 2005). PKC modifies the function of other 
proteins, including transmembrane channels, e.g. Nav1.8, Nav1.9 and TRPV1 (Khasar 
et al. 1999; Premkumar and Ahern 2000; Vellani et al. 2001; Numazaki et al. 2002; 
Shin et al. 2002; Baker 2005). Loss of either bradykinin receptor (either in knockout 
mice or by using antagonists) results in reduced responses to painful stimuli (Rupniak 
et al. 1997; Pesquero et al. 2000).  
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Cyclooxygenase (COX) mediates the conversion of arachidonic acid into prostanoids. 
Analogous to the B1 and B2 receptors, COX-1 is constitutively expressed whereas 
COX-2 is induced by inflammation. Prostaglandins act as sensitisors by stimulating 
the production of Protein kinase A (PKA) and PKC, which mediate voltage-gated 
sodium channel and TRPV1 function, thus increasing sensory afferent excitability 
(Fitzgerald et al. 1999; Matsumoto et al. 2005). Prostaglandin E2 (PGE2) also 
increases the proportion of DRG neurons that respond to the application of 
bradykinin (Stucky et al. 1996) as well as the magnitude of response (Mense 1981; 
Brunsden and Grundy 1999). Addition of PGE2 to a jejunal nerve preparation restores 
the bradykinin response that was partially blocked by a COX blocker, naproxen, 
suggesting that PGE2 is required for the full response to bradykinin (Maubach and 
Grundy 1999). 
 
1.2.4 Sensitisation 
Persistent inflammation can cause increased expression of a channel or increased 
trafficking of the channel to the peripheral terminal (Ji et al. 2002). In addition, the 
release of pro-inflammatory agents at the site of injury may lead to peripheral 
sensitisation (Bueno et al. 2000) which is a form of stimulus-induced nociceptor 
plasticity characterised by increased spontaneous activity, an increased response to 
stimuli and a reduction in the threshold required to initiate an action potential. 
These characteristics may clinically manifest as spontaneous pain, hyperalgesia 
(exaggerated response to a stimulus) and allodynia (response to a previously 
innocuous stimulus). These phenomenon occur both in the somatic and visceral 
systems. Peripheral sensitisation can occur through 3 different mechanisms: a 
change in receptor sensitivity, an increase in the numbers of receptors or through 
the expression of new receptors (Kirkup et al. 2001). In principal, peripheral 
sensitisation is transient with the response properties of primary afferents returning 
to their normal state after resolution of the inflammatory episode (Mayer and 
Tillisch 2011). 
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A similar chain of events occurs centrally. The increased release of pre-synaptic 
neurotransmitters that occurs with peripheral sensitisation increases the activation 
of PKA and PKC. This leads to changes in CNS receptor kinetics, e.g. lowering of the 
activation threshold, that enhance their responsiveness (Knowles and Aziz 2009). As 
the majority of synaptic input is subthreshold (Woolf and King 1989), the lowering of 
the threshold allows conversion of these previously subthreshold inputs into action 
potentials. This is termed central sensitisation. In central sensitisation, the pain is not 
coupled to the presence, intensity or duration of a noxious stimulus and is due to a 
shift in the sensory system from high-threshold nociception to low-threshold pain 
hypersensitivity (Latremoliere and Woolf 2009). This corresponds to an 
enhancement in the functional status of the nociceptive pathways by an increase in 
membrane excitability, synaptic efficacy or reduced inhibition. Due to the 
convergence of numerous nerves in the CNS, central sensitisation often has effects 
on neurons adjacent to those that exhibit peripheral sensitisation. This leads to 
hyperalgesia in those neighbouring nerves, termed secondary hyperalgesia, and 
affects both visceral and somatic afferents (Figure 4).  
 
Figure 4 Illustration of an area of primary hyperalgesia surrounding a focus of injury.  In addition, 
central sensitisation leads to development of a larger area of secondary hyperalgesia. Modified from 
Galer et al 2002.  
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1.3 Role of voltage-gated sodium channels in nociception 
 
1.3.1 Introduction 
Voltage-gated sodium channels (Nav) are transmembrane proteins that are essential 
for the generation of action potentials. Each channel is coded for by 1700-2000 
amino acids and formed by an α subunit (260 kDa) which acts as the core protein 
and auxiliary β subunits (33-36 kDa) which modify channel function (Catterall 2000). 
Each α subunit has 4 homologous domains each of which is made up of 6 
transmembrane segments with a pore-forming loop between segments 5 and 6 
(Figure 5). The short intracellular loop connecting domains III and IV serves as the 
inactivation gate for the channel (Catterall et al. 2005). The α subunit contains all the 
features of a functional ion channel including the voltage sensor, the activation and 
inactivation gates and the binding sites for tetrodotoxin and other blockers as well as 
phosphorylation sites (Cantrell and Catterall 2001). Four β subunits exist and they 
have differential distribution depending on the size of the neuron with β1 and β3 
being the predominant subunits of large and small neurons respectively (Ho et al. 
2012). The individual β subunits have been shown to have differing modulatory 
effects on Nav function, for example β3 regulates Nav1.7 activation while β1 
regulates inactivation of the channel (Ho et al. 2012).  
 
 
Figure 5 Structure of the α subunit of voltage-gated sodium channels. Each subunit is made of 4 
homologous domains (I-IV) which are made of 6 trans-membrane segments (1-6). The pore is formed 
by loops between segments 5 and 6 of each domain. 
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There are 10 α subunits in total, with nine belonging to the same family (Figure 6). 
The tenth member (Nax) is 50% identical to the other channels but is thought to be 
activated by changes in Na+ concentration rather than the membrane potential 
(Hiyama et al. 2002; Catterall et al. 2005). From an evolutionary standpoint, Nav1.1, 
Nav1.2, Nav1.3 and Nav1.7 are thought to be closely related having genes located on 
human chromosome 2q23-24, while Nav1.5, Nav1.8 and Nav1.9 form another 
subfamily located on 3p21-24 (Catterall et al. 2005).  
 
Figure 6 Phylogenetic tree of rat voltage-gated sodium channel α subunits. From Catterall et al 2005. 
 
Collectively, Nav channels are distributed throughout the body but individual 
channels have restricted distribution (Table 1 and figure 7). The channels are also 
categorised by their sensitivity to the puffer fish poison, tetrodotoxin (TTX) with 
most channels sensitive to nM concentrations of TTX while others (Nav1.5, Nav1.8 & 
Nav1.9) are resistant to mM concentrations of TTX. Nav1.7-1.9 are the dominant 
peripheral nervous system (PNS) channels with Nav1.8 and Nav1.9 expressing a TTX 
resistant (TTX-r) current while Nav1.7 expresses a TTX sensitive current (TTX-s) 
(Catterall et al. 2005). 
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Channel Predominant 
location 
Sensitivity to 
tetrodotoxin 
Chromosomal 
location 
Nav1.1 CNS/PNS Sensitive 2q24 
Nav1.2 CNS Sensitive 2q23-24 
Nav1.3 Embryonic CNS Sensitive 2q24 
Nav1.4 Skeletal muscle Sensitive 17q23-25 
Nav1.5 Heart Resistant 3p21 
Nav1.6 CNS/PNS Sensitive 12q13 
Nav1.7 PNS Sensitive 2q24 
Nav1.8 PNS Resistant 3p22-24 
Nav1.9 PNS Resistant 3p21-24 
Table 1 Distribution, chromosomal location and tetrodotoxin sensitivity of the voltage-gated 
sodium channels. PNS – peripheral nervous system, CNS – central nervous system. From Ogata and 
Ohishi 2002.  
 
 
Figure 7 Expression of Nav transcripts in rat DRG neurons. Small (<25µm) and large (>30µm) 
diameter neurons were individually harvested with the mRNA in the cell lysates reverse transcribed 
and quantified using TaqMan real-time polymerase chain reaction. The data are the means and 
standard errors of 71 small and 90 large diameter neurons. mRNA messenger ribonucleic acid. From 
Ho and O’Leary 2011.  
George Boundouki 
 
 
 39 
1.3.2 Role of Nav in pain models 
Because of their role in action potential generation, Navs contribute to the 
development of neuropathic and inflammatory pain. Neuropathic pain results from 
changes in the nerve structure, e.g. transection or avulsion of the nerve, whereas 
inflammatory pain develops as a result of changes in the environment surrounding 
the nerve, e.g. release of mediators during the inflammatory process. Thus, 
inflammatory pain may be somatic or visceral in origin whereas there is no 
established visceral model of neuropathic pain (although peripheral nerves are 
transected or ligated at surgery whenever the mesentery is divided).  
 
1.3.2.1 Neuropathic pain models 
A number of voltage-gated sodium channels have been shown to play a role in the 
development of neuropathic pain and subsequent hyperalgesia. 
 
1.3.2.1.1 Nav1.3 
Nav1.3, which is normally present at very low levels in adult DRG (Waxman et al. 
1994), is significantly up-regulated following peripheral nerve injury in both rodents 
(Fjell et al. 1999; Waxman et al. 1999; Hains et al. 2003) and man (Black et al. 2008); 
and consequently its current becomes the dominant TTX-s current (Black et al. 
1999). These changes are attenuated by application of nerve growth factor (NGF) 
and glial-derived neurotrophic factor (GDNF) which reverse the increase in Nav1.3 
expression and ameliorate behavioural responses (Boucher et al. 2000; Leffler et al. 
2002). In addition, application of antisense oligodeoxynucleotides to Nav1.3 
decreases the mechanical and thermal hyperalgesia induced by the nerve injury 
implying a role for Nav1.3 in the maintenance of the hyperalgesia (Hains et al. 2003). 
 
1.3.2.1.2 Nav1.7 
Peripheral nerve injury causes down-regulation of Nav1.7 transcript levels in rodents 
(Kim et al. 2002; Berta et al. 2008) whereas in man, immunoreactivity to Nav1.7 
George Boundouki 
 
 
 40 
increases in human neuromas (Kretschmer et al. 2002; Bird et al. 2007; Black et al. 
2008). This contradiction may reflect inter-species differences in the contribution of 
Nav1.7 to pain signalling as evidenced by the debilitating hereditary pain syndromes 
caused by gain-of-function mutations in Nav1.7 in man (see section 1.3.2.2.1) or 
methodological issues, particularly the specificity of human antibodies. 
 
1.3.2.1.3 Nav1.8  
Nav1.8 expression is downregulated in injured neurons in rodent neuropathic pain 
models (Dib-Hajj et al. 1996; Dib-Hajj et al. 1999a; Decosterd et al. 2002; Lai et al. 
2002; Zhang et al. 2004). However, in uninjured neighbouring neurons, the 
expression of Nav1.8 is increased (Decosterd et al. 2002; Gold et al. 2003; Zhang et 
al. 2004). Data from studies using antisense or Nav1.8 knockout mice show a 
reduction in mechanical and thermal hyperalgesia after elimination of Nav1.8 
(Akopian et al. 1999; Lai et al. 2002; Nassar et al. 2005). The hyperalgesia is also 
reduced by application of a small molecule blocker of Nav1.8 (Jarvis et al. 2007). The 
expression of Nav1.8 is also upregulated in painful neuromas in man (Coward et al. 
2000; Black et al. 2008). The apparently paradoxical findings of decreased expression 
of Nav1.8 in injured neurons and the decrease in hypersensitivity derived from 
blocking Nav1.8 suggests that the role played by Nav1.8 in neuropathic pain results 
from its redistribution to uninjured neurons.  
 
1.3.2.1.4 Nav1.9 
In both rodent (Dib-Hajj et al. 1998; Sleeper et al. 2000; Decosterd et al. 2002; Priest 
et al. 2005; Amaya et al. 2006) and man (Coward et al. 2000; Black et al. 2008), 
studies have failed to show a role for Nav1.9 in the development of neuropathic pain.  
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1.3.2.2 Inflammatory pain models 
There is significant evidence in support of a role for voltage-gated sodium channels 
in the development of pain and hypersensitivity after inflammation in both the 
somatic and visceral systems.  
 
1.3.2.2.1 Nav1.7 
In the rodent somatic system, Nav1.7 expression is upregulated after injection of CFA 
(Gould et al. 2004), carrageenan (Black et al. 2004) or NGF (Gould et al. 2000). 
Removal of Nav1.7 activity from nociceptors, e.g. by using conditional knock out or 
antisense, reduces the inflammatory pain responses as well as the ensuing 
hyperalgesia (Nassar et al. 2004; Yeomans et al. 2005). No studies have investigated 
a role for Nav1.7 in the development of visceral inflammatory pain.  
 
In man, Nav1.7 gain of function mutations cause primary erythromelalgia and 
paroxysmal extreme pain disorder while loss of function mutations lead to 
congenital insensitivity to pain in individuals who have a reduced sense of smell but 
are otherwise normal (Dib-Hajj et al. 2007). There have been reports of individuals 
suffering from osteomyelitis, cellulitis and acute appendicitis without experiencing 
any pain (Cox et al. 2006; Goldberg et al. 2007). A recent clinical study showed that 
the administration of a Nav1.7 blocker reduces pain in patients suffering from 
primary erythromelalgia (Goldberg et al. 2012). These studies provide compelling 
evidence of a role for Nav1.7 in both somatic and visceral inflammatory pain in man.  
 
1.3.2.2.2 Nav1.8 
In the rodent somatic system, Nav1.8 expression and current are increased in 
response to a variety of inflammatory mediators including CFA, carrageenan and 
GDNF (Cummins et al. 2000; Black et al. 2004; Coggeshall et al. 2004). The expression 
of Nav1.8 has also been shown to be increased in a TNBS model of colitis (King et al. 
2009). Studies using Nav1.8 -/- mice, antisense oligodeoxynucleotides or small 
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molecule blockers have demonstrated a role for Nav1.8 in the response of visceral 
(Laird et al. 2002; Jarvis et al. 2007) and somatic (Akopian et al. 1999; Kerr et al. 
2001; Abrahamsen et al. 2008; Joshi et al. 2009) afferents to inflammatory mediators 
and the consequent development of thermal and mechanical hyperalgesia.  
 
In man, increased expression of Nav1.8 has been observed in pulp from painful teeth 
(Renton et al. 2005). These studies highlight the role that Nav1.8 plays in the early 
stages of the inflammatory response as well as in the development of hyperalgesia 
that is the hallmark of sensitisation. 
 
1.3.2.2.3 Nav1.9 
Nav1.9 expression and current are increased in response to a variety of inflammatory 
mediators suggesting that Nav1.9 plays a role in inflammatory pain signalling. As it is 
the subject of this thesis, Nav1.9 is fully discussed in section 1.4 below.  
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1.4 Nav1.9 
 
1.4.1 Identification 
Dorsal root ganglia neurons express a sodium current which includes a strong TTX-r 
element (Rizzo et al. 1994) and Nav1.8 was identified as the channel responsible for 
this current in 1996 (Akopian et al. 1996). However, patch clamp studies 
demonstrated an underlying heterogeneity in the TTX-r current which implied that 
more than one channel was responsible for the overall TTX-r current (Rush and 
Elliott 1997; Schild and Kunze 1997). Indeed, a TTX-r current was recorded in Nav1.8 -
/- mice (Cummins et al. 1999). Nav1.9 was first cloned in rat in 1998 and expressed a 
TTX-r current with different characteristics to Nav1.8 (Dib-Hajj et al. 1998; Tate et al. 
1998). This was followed by the first reports in mouse and man one year later (Dib-
Hajj et al. 1999b; Dib-Hajj et al. 1999c).  
 
1.4.2 Structure 
As with all sodium channels, the structure of Nav1.9 consists of α and β subunits. The 
types of β subunits are yet to be established (Catterall et al. 2005) but are likely to be 
β2 and β3 as these are the predominant β subunits in small diameter afferents (Ho 
et al. 2012). In rat and mouse, Nav1.9 is formed of 1765 residues (1792 residues in 
man) with a serine in domain 1 predicting resistance to TTX (Dib-Hajj et al. 2002). 
The rat α subunit exhibits only 42-53% similarity to other mammalian Navs (Dib-Hajj 
et al. 1998). Mouse and rat Nav1.9 are 91% similar to each other and the human 
channel is 80% similar to both (Dib-Hajj et al. 1999b). 
 
1.4.3 Biophysical characteristics 
Recordings of Nav1.9 current have been made from dorsal root and trigeminal 
ganglia (TG) soma and neurons as well as myenteric ganglia in mouse, rat, guinea pig 
and man. The current is described as slow, persistent and resistant to TTX, with 
activation thresholds ranging from -80 mV to -58 mV depending on the cell line and 
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protocol used (Tate et al. 1998; Cummins et al. 1999; Dib-Hajj et al. 1999b; Baker et 
al. 2003; Coste et al. 2004; Priest et al. 2005; Amaya et al. 2006; Li and Schild 2007; 
Padilla et al. 2007; Zheng et al. 2007; Maingret et al. 2008; Ostman et al. 2008; Qiao 
et al. 2009; Ho and O'Leary 2011). Thus, the Nav1.9 activation threshold is more 
negative than that of the other Navs, particularly Nav1.8 (Tate et al. 1998; Fjell et al. 
1999; Baker et al. 2003; Coste et al. 2004; Zheng et al. 2007) with which it is closely 
expressed (Figure 8) (Tate et al. 1998; Amaya et al. 2000; Sleeper et al. 2000; Amaya 
et al. 2006). Because of its activation at potentials close to the resting membrane 
potential, Nav1.9 is thought to contribute to setting the membrane potential 
(Cummins et al. 1999; Herzog et al. 2001; Baker et al. 2003), modulation of neuronal 
excitability close to the resting potential (Cummins et al. 1999) and enhancement of 
the response to inputs that are sub-threshold (Herzog et al. 2001; Rush and Waxman 
2004). 
 
Figure 8 The voltage dependence of activation of Nav1.7-1.9. Nav1.9 activates at potentials more 
negative and closer to the resting membrane potential than Nav1.8 and Nav1.7. Modified from Momin 
and Wood 2008.  
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1.4.4 Cellular distribution 
Nav1.9 is preferentially distributed in small diameter neurons and has been shown to 
be present in 56-83% of fibres less than 30 µm in diameter (Dib-Hajj et al. 1998; Fjell 
et al. 2000; Fang et al. 2002). Although an early report found no Nav1.9 labelling of 
myelinated fibres (Amaya et al. 2000), others, including from the same group, have 
shown Nav1.9 in a small minority of Aδ and Aβ fibres (Fjell et al. 2000; Decosterd et 
al. 2002; Fang et al. 2002; Coggeshall et al. 2004; Fukuoka et al. 2008). A significant 
negative relationship has been described between Nav1.9 staining intensity and DRG 
neuronal size and conduction velocity (Coward et al. 2000; Fang et al. 2002) as well 
as TG neuronal size (Wells et al. 2007). This indicates that Nav1.9 is expressed most 
intensively on nociceptive C fibres.  
 
1.4.4.1 Tissue distribution 
Nav1.9 has been described in a variety of tissues including rodent DRG and TG (Dib-
Hajj et al. 1998; Tate et al. 1998; Amaya et al. 2000; Fang et al. 2002; Beyak et al. 
2004; Amaya et al. 2006; Fang et al. 2006; Hillsley et al. 2006; Padilla et al. 2007; 
Fukuoka et al. 2008; Strickland et al. 2008; Fukuoka and Noguchi 2011; Ho and 
O'Leary 2011) as well as on nodes of Ranvier of small diameter fibres (Fjell et al. 
2000). In addition, Nav1.9 has been demonstrated in rodent cornea (Dib-Hajj et al. 
1998; Fjell et al. 2000), dental pulpal afferents (Padilla et al. 2007), digital nerves 
(Coggeshall et al. 2004) and in the epidermis of the paws (Persson et al. 2010) and 
lips (Padilla et al. 2007). In the visceral system, Nav1.9 has been demonstrated on 
bladder (Black et al. 2003) and colonic (Hillsley et al. 2006; King et al. 2009) 
afferents. In man, Nav1.9 has been shown in DRG soma and neurons (Coward et al. 
2000), TG neurons and dental pulpal afferents (Wells et al. 2007) as well as brachial 
nerves and painful neuromas (Black et al. 2008). 
 
In the enteric nervous system, Nav1.9 has been demonstrated in guinea pig (Rugiero 
et al. 2003), rat (Rugiero et al. 2003; Padilla et al. 2007) and mouse (Padilla et al. 
2007) myenteric neurons and submucosal plexi and in the interplexus tracts running 
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between myenteric and submucosal ganglia (Padilla et al. 2007). Nav1.9 was not seen 
in rat cerebellum, spinal cord, heart, kidney, liver or muscle (Dib-Hajj et al. 1998).  
 
The above studies demonstrate that Nav1.9 is distributed widely in both the somatic 
and visceral systems with no evidence of its presence in the CNS thus positioning it 
as an attractive analgesic target. 
 
1.4.4.2 Co-localisation of Nav1.9 with other markers 
Nav1.9 has been co-localised with a number of neuronal markers and other ion 
channels. Between 72% and 99% of Isolectin B4 (IB4) +ve and 27% and 56% of IB4 -
ve fibres demonstrated staining for Nav1.9 (Fjell et al. 1999; Fjell et al. 2000; Fukuoka 
et al. 2008) with the difference probably accounted for by the differing criteria used 
to define positive staining. IB4 is used in the somatic system as a marker of 
nociceptors and Fang et al (2006) concluded that intensity of IB4 staining was 
positively related to Nav1.9 staining. Nav1.9 has also been shown to co-localise with 
the bradykinin B2 receptor (Amaya et al. 2006), TRPV1 (Amaya et al. 2000; Amaya et 
al. 2006; Padilla et al. 2007) and P2X3 (Amaya et al. 2006). This is unsurprising as the 
presence of these receptors is a hallmark of nociceptors. This close co-expression 
allows for modulation of the function of these receptors by one another. 
  
1.4.5 Effect of inflammatory mediators on Nav1.9 current and expression 
Various studies, mostly in vitro, have investigated the effect of inflammatory 
mediators on Nav1.9 current. Guanosine triphosphate (GTP) and its analogue GTP-γ-S 
have been shown to enhance the Nav1.9 current in both mouse and rat (Baker et al. 
2003; Maingret et al. 2008) by acting through PKC (Baker 2005). ATP has been shown 
to increase Nav1.9 current via PKC (Baker 2005). TNFα also increases the Nav1.9 
current in cultured rat DRG (Chen et al. 2011). Conflicting data have been reported 
with regards to the relationship between PGE2 and Nav1.9. A number of authors 
were unable to demonstrate an effect of PGE2 on Nav1.9 current (Baker 2005; Zheng 
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et al. 2007; Maingret et al. 2008). On the other hand, two studies demonstrated an 
increase in Nav1.9 current after application of PGE2 (Rush and Waxman 2004; Li and 
Schild 2007). Maingret et al (2008) failed to demonstrate an effect of bradykinin, 
PGE2, histamine, noradrenalin or ATP on Nav1.9 current when these mediators were 
added separately. However, an ‘inflammatory soup’ containing all the mediators 
caused an increase in the current and a decrease in the threshold for excitability. The 
discrepancy in these findings may be a reflection of the inherent difficulties in using 
an artificial system to replicate complex intracellular events. 
 
These studies demonstrate that, at DRG level, the Nav1.9 current is enhanced in 
response to a variety of inflammatory mediators with PKC as one mechanism for the 
action of these mediators. Investigators have also used rodent pain models to 
investigate the role of Nav1.9 in the development of neuropathic and inflammatory 
pain. 
 
1.4.6 Role of Nav1.9 in pain models 
 
1.4.6.1 Neuropathic pain models 
A number of models are used to induce neuropathic pain in rodents. These include 
spinal nerve ligation (Kim and Chung 1992), spared nerve injury (ligation and 
axotomy of 2 of the 3 branches of the sciatic nerve) (Decosterd and Woolf 2000), and 
peripheral axotomy. These models induce spontaneous pain and hyperalgesia in the 
affected dermatomes.  
 
Using these models, several authors have demonstrated decreased expression of 
Nav1.9 with a concurrent reduction in its current after induction of the injury (Dib-
Hajj et al. 1998; Dib-Hajj et al. 1999a; Boucher et al. 2000; Cummins et al. 2000; 
Sleeper et al. 2000; Decosterd et al. 2002; Berta et al. 2008). A model of neuropathic 
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pain involving leg lengthening leading to sural nerve elongation also demonstrated a 
reduction in Nav1.9 messenger ribonucleic acid (mRNA) levels (Ohno et al. 2010). 
Behavioural studies have failed to demonstrate any differences between Nav1.9 -/- 
and +/+ mice in the development of mechanical or thermal hyperalgesia that are 
induced by these models (Priest et al. 2005; Amaya et al. 2006). In agreement with 
rodent studies which have failed to demonstrate a role for Nav1.9 in the 
development of neuropathic pain, there is no change in Nav1.9 expression in painful 
neuromas in man (Coward et al. 2000; Black et al. 2008).  
 
1.4.6.2 Inflammatory pain models 
Inflammatory pain models have been used to investigate the role of Nav1.9 in the 
development of acute somatic pain behaviour or hyperalgesia after induction of 
inflammation by a variety of mediators including carrageenan, CFA, formalin, PGE2, 
bradykinin and capsaicin (Bannon 2001; Fehrenbacher et al. 2012). Models of 
visceral inflammatory pain include the induction of inflammation in the small or 
large bowel (Stadnyk et al. 1990; Scheiffele and Fuss 2002) as well as instillation of 
inflammatory mediators into the viscera, e.g. colon or bladder.  
 
Using the somatic pain models, a number of authors have shown increased 
expression of Nav1.9 after intraplantar injection of CFA or carrageenan (Tate et al. 
1998; Amaya et al. 2006; Strickland et al. 2008; Lolignier et al. 2011). Behavioural 
studies have demonstrated that knockout of Nav1.9 results in a significant 
attenuation of the pain behaviour, e.g. licking or flinching, as well as the thermal and 
mechanical hyperalgesia that develop after injection of CFA, carrageenan or formalin 
(Priest et al. 2005; Amaya et al. 2006; Lolignier et al. 2011). In addition, injection of 
bradykinin, capsaicin, PGE2 and ATP also produced behavioural pain responses and 
mechanical and thermal hyperalgesia that were attenuated in Nav1.9 -/- mice 
(Amaya et al. 2006). In man, Nav1.9 expression has been shown to increase in 
inflamed dental pulp axons (Wells et al. 2007). 
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While studies investigating TNBS colitis and transient jejunitis did not show any 
effect of inflammation on Nav1.9 expression or current (Beyak et al. 2004; Hillsley et 
al. 2006; King et al. 2009), using a pain model for IBS, Martinez and Melgar (2008) 
demonstrated that, during an acute inflammatory episode, Nav1.9 -/- mice do not 
show the increased visceromotor reflex to colorectal distension experienced by 
Nav1.9 +/+ mice. In addition, a study investigating bladder afferents demonstrated a 
reduction in afferent activation in response to PGE2 in Nav1.9 -/- mice (Ritter et al. 
2009). In contrast, Leo et al (2010) found an increase in the number of abdominal 
writhes in response to acetic acid in Nav1.9 -/- as compared to +/+ mice. The 
conflicting results from models of colonic inflammation may be accounted for by the 
variation in the inflammation caused or by the time period between induction of 
infection and testing, e.g. 5 hours for the Martinez study compared to up to 25 days 
for the Hillsley study. 
 
In summary, data from both somatic and visceral pain models provide evidence for a 
role for Nav1.9 in the response of afferents to inflammation.  
 
1.4.7 Effect of knock-out of Nav1.9 on other Navs 
Priest et al (2005) reported marginal increases in Nav1.1, 1.2, 1.3, 1.7 and 1.8 mRNA 
in Nav1.9 -/- mice but Amaya et al (2006) showed no change in mRNA levels of 
Nav1.1, 1.3, 1.5, 1.7 and 1.8. They also found no change in the TTX-s or Nav1.8 
currents. The differences in mRNA levels between the studies may be explained by 
the fact that Amaya used 3 DRG from 3 animals in each group (Nav1.9 +/+ vs. -/-) 
whereas Priest only used one DRG from each of the 4 animals in each group. Overall, 
the data show that there is minimal, if any, increase in the expression of the other 
Navs in the Nav1.9 -/- animals. In addition, as discussed above, Nav1.9 transduces a 
unique persistent current that is activated at thresholds below those of the other 
Nav channels. Thus, even a small increase in the expression of these other channels 
in Nav1.9 -/- animals will not replace the current lost due to knock out of Nav1.9.  
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1.4.8 Effect of knock-out of Nav1.9 on general behaviour 
Nav1.9 -/- mice are indistinguishable from +/+ littermates in respect of moving, 
climbing and fertility. Amaya et al (2006) and Priest et al (2005) demonstrated that 
the response to Von Frey probing and exposure to heat and cold stimuli were not 
changed in Nav1.9 -/ - mice while Ritter et al (2009) found no difference in bladder 
capacity or voided volumes. This indicates that there are no global deleterious 
effects to knocking-out Nav1.9 (in contrast to global knockout of Nav1.7 which is fatal 
soon after birth (Nassar et al. 2004)). 
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1.5 Summary 
Abdominal pain places a large burden on society and its current management is sub-
optimal due to the lack of visceral-specific analgesics. Voltage-gated sodium 
channels are crucial for action potential generation and Nav1.9 has the lowest 
activation threshold of all these channels. In addition, Nav1.9 expresses a unique, 
slow, persistent current and is peripherally expressed on small diameter DRG 
neurons. Whereas, at the level of the DRG, the Nav1.9 current is enhanced in 
response to a number of inflammatory mediators, no data exist for the role of Nav1.9 
in signalling at the nerve terminal. Behavioural studies in mice have established a 
role for Nav1.9 in the response of somatic afferents to inflammatory mediators 
where it has a role in the immediate response of the afferents as well as in the 
development of hyperalgesia. No studies have investigated the role of Nav1.9 in the 
response of visceral afferents to inflammatory and mechanical stimuli.  
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1.6 Aim and hypotheses 
 
1.6.1 Aim 
The aim of this project was to investigate the role of Nav1.9 in visceral afferent 
signalling. A number of individual inflammatory mediators as well as a human 
inflammatory supernatant were tested to investigate whether Nav1.9 plays a role in 
the response of afferents to these mediators. In addition, luminal distension of 
segments of gastrointestinal tissue was used to investigate whether Nav1.9 plays a 
role in the response of the afferents to mechanical stimulation.  
 
1.6.2 Hypotheses 
The following hypotheses were tested: 
1. The visceral afferent response to a variety of individual inflammatory 
mediators is reduced in Nav1.9 -/- mice. 
2. The visceral afferent response to an inflammatory supernatant generated 
from inflamed human gastrointestinal tissue is reduced in Nav1.9 -/- mice.  
3. Prostaglandins play a role in the activation of visceral afferents in response to 
inflammatory stimulation via a Nav1.9 mediated pathway. 
4. Nav1.9 plays a role in the response of visceral afferents to luminal distension.  
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2  
Materials and Methods 
 
2.1 Animals 
Colonies of Nav1.9 +/+ and Nav1.9 -/- mice bred on a C57BL/6 background were re-
derived from Nav1.9 +/- mice in accordance with the United Kingdom Animals 
(Scientific Procedures) Act 1986. The Nav1.9 -/- mice used in the generation of the 
heterozygous breeding pairs were generated as previously described (Ostman et al. 
2008). Briefly, an RPCI-22 129S6/SvEvTac mouse BAC library was screened for 
Nav1.9. Deoxyribonucleic acid (DNA) from Nav1.9 BAC clones was prepared and 
subcloned into pBluescript (BS-SKII). The 5’-arm, containing exons 2 and 3, of the 
SCN11A gene was a 4.8 kb EcoRI–NsiI fragment. The 3’ arm containing exons 6–10 
was a 7.2 kb AccI–Smal fragment. The two arms were inserted around a neomycin 
cassette. Hence, exons 4 and 5 of the SCN11A gene were replaced by the neomycin 
resistance cassette which deletes domain 1 in the S4 voltage sensor of the Nav1.9 
channel. Cells were selected with G418 and correctly targeted single-copy 
integrations were identified using Southern blots. Chimeras were crossed with 
C57BL/6 and germ line transmission tested using Southern blotting of genomic DNA 
from pinna biopsies. For Southern blots, DNA was digested with BamHIand probed 
with a 500 bp SacI-EcoRI fragment 5’-to 5’-arm. The mice were maintained in a 
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barrier facility with a 12 hour light/dark cycle and had ad libitum access to food and 
water. At the time of weaning, pinna biopsies were obtained for genotyping. In the 
initial experiments on intestinal nerves, C57BL/6 mice were used as controls (Charles 
Rivers, UK). Follow-up intestinal experiments used Nav1.9 +/+. There was no 
difference in the response between C57BL/6 and Nav1.9 +/+ so the two groups were 
analysed as one for this thesis. 
 
2.1.1 Genotyping 
Pinna biopsies were submerged in 500 µl of lysis buffer (0.1 M Tris-HCl, 5 mM 
ethylenediaminetetraacetic acid (EDTA), 0.2% sodium dodecyl sulfate (SDS), 20 mM 
sodium chloride (NaCl), 50 µg proteinase K) for 6 hours at 50 ˚C. The mixture was 
then centrifuged at 5000 revolutions per minute (RPM) for 15 seconds and the 
supernatants transferred to clean tubes. The supernatant was then mixed 1:1 with 
isopropanol and centrifuged at 13000 RPM for 15 minutes at 4 ˚C. The supernatant 
was decanted, 500 µl of 70% ethanol added, and then centrifuged at 13000 RPM for 
10 minutes at 4 ˚C. The supernatant was again decanted and the pellet allowed to 
dry overnight. On the next morning, 40 µl of sterile water was added and the 
concentration of DNA in each sample was determined using a Nanodrop 
spectrophotometer (Thermo Scientific, UK). Approximately 50-70 ng of DNA were 
mixed with HotStarTaq (Qiagen, UK) and purpose designed primers (common: 5′-
ATGTGGCACTGGGCTTGAACTC-3′; wildtype: 5′-AACAGTCTTACGCTGTTCCGATG-3′; 
mutant: 5′-CTCGTCGTGACCCATGGCGAT-3′) and sterile water in a 1:5:1:1:2 ratio by 
volume (DNA: HotStarTaq: common primer: mutant/wild type primer: sterile water). 
The polymerase chain reaction (PCR) was started at 95 ˚C for 15 minutes followed by 
35 cycles of: 95 ˚C for 1 minute, 57 ˚C for 1 minute and 72 ˚C for 2 minutes. Ten µl of 
PCR products were then mixed with 2 µl glycerol dye and loaded onto a 1% agarose 
gel containing 0.5% ethidium bromide. The electrophoresis reaction was run at 100 V 
for 25 minutes (VWR, UK) before the gel was transferred to a UV chamber (Syngene, 
UK) and images obtained using GeneSnap software (Syngene, UK). A band at 300 
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base pairs (bps) was visible for the wild-type gene and at 600 bp for the mutated 
gene.  
2.2 Human Tissue 
Human appendices were obtained from patients undergoing surgery at the Royal 
London Hospital (part of Barts Health NHS Trust). The patients underwent surgery 
either for cancer (normal appendices) or a clinical diagnosis of appendicitis (inflamed 
appendices). Patients were approached prior to surgery, the research project 
explained and an information leaflet provided. Patients who agreed to take part 
were asked to sign a consent form. The collection and use of human tissue was 
approved by the local NHS ethics committee (REC 10/H0703/71). After generation of 
the supernatants (described below), specimens were fixed in formalin and delivered 
to the NHS pathology laboratory to be subjected to routine histological examination. 
The histology report was subsequently checked to confirm whether the appendices 
were microscopically inflamed or not. Four of the six inflamed appendices were 
classified as suppurative while 2 were gangrenous (Carr 2000). The patients’ white 
blood cell counts were also recorded. 
 
2.2.1 Generation of human supernatants 
The appendices were weighed and then incubated at 37 ˚C in carbogenated Krebs 
buffer – in mM: 124 NaCl, 4.8 potassium chloride (KCl), 1.3 monosodium phosphate 
(NaH2PO4), 2.5 calcium chloride (CaCl2), 1.2 magnesium sulphate (MgSO4), 11.1 
glucose, and 25 sodium bicarbonate (NaHCO3). The volume of buffer was 2.5 times 
the weight of tissue. After 25 minutes incubation, the appendix was removed and 
the buffer was spun at 2000 RPM for 10 minutes. The supernatant was then 
decanted and stored at -80 ˚C until use. 
 
2.2.2 Measurement of cytokine concentration of human supernatants 
The concentration of a selected number of cytokines in the human supernatants was 
measured using a Magpix reader (Luminex, UK). A five cytokine assay was chosen 
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(TNF-α, IL-1β, IL-6, IL-8 and GM-CSF; catalogue number LHC0003M, Invitrogen, UK). 
The system is based on ELISA principles. 50 µl of each supernatant were mixed with 
an equal volume of dilution buffer and then incubated with the magnetic beads for 2 
hours. After 3 serial washes with wash buffer, the beads were incubated with a 
biotinylated antibody for 1 hour followed by further washes and then incubation 
with streptavidin-RPE for 30 minutes. Further washes were performed and then the 
bead fluorescence measured and compared with that of the standards (which were 
serially diluted 8 times). The supernatants were analysed in duplicates. The 
concentration of a particular cytokine in some samples was below the detection 
threshold and the software returned a reading of “<x.xxx”. In these situations, the 
value of x.xxx was taken as the concentration.  
 
2.3 Electrophysiology 
 
On the day of the experiment, the animal (male or female, 12-28 weeks) was 
sacrificed by exposure to rising carbon dioxide (CO2) concentration followed by 
exsanguination. For intestinal nerve experiments, the intestine and mesentery were 
dissected from the ligament of Treitz to the terminal ileum. For colonic nerve 
experiments, the colon was dissected from the caecum down to anus including the 
aorta and associated nerve bundle. The intestine or colon was then placed in ice cold 
Krebs buffer (in mM: 124 NaCl, 4.8 KCl, 1.3 NaH2PO4, 2.5 CaCl2, 1.2 MgSO4, 11.1 
glucose, and 25 NaHCO3). Preparations contained the prostaglandin synthesis 
inhibitor indomethacin (3 µM) to reduce the effect of prostaglandins on nerve 
activity and both the calcium channel antagonist nifedipine (10 µM) and muscarinic 
acetylcholine receptor antagonist atropine (10 µM) to suppress contractions due to 
smooth muscle activity which would interfere with the nerve recording. Following 
gross dissection of the segment of intestine or colon as described below, it was 
transferred to a bespoke recording chamber whose base was lined with sylgard (Dow 
Corning, USA) and which was filled with continuously carbogenated (95% O2, 5% 
CO2) Krebs buffer (7 ml/min; 32-34 ˚C). The ends of the segment of intestine or colon 
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were tied to cannula and the tissue luminally perfused at 0.1 ml/min. The dissected 
nerve fibre was then drawn into a borosilicate glass suction electrode (Harvard 
Apparatus, UK) to allow the acquisition of a multi-unit recording (Figure 9). Nerve 
activity was recorded on a Neurolog headstage (Neurolog, UK), amplified (gain 5k), 
filtered (band pass 100-2000 Hz) and acquired (20 kHz sampling rate) via a Micro 
1401 MKII (Cambridge Electronic Design, UK) to a desktop computer running Spike 2 
software (Cambridge Electronic Design). The threshold level for action potential 
counting was set to twice the background noise level.  
 
 
  
Figure 9 The recording chamber with a segment of colon tied to the perfusion cannula, its mesentery 
dissected and a nerve in the suction electrode. 
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2.3.1 Intestinal nerve dissection 
For intestinal nerve recordings, a 3-4 cm segment of intestine, starting most distally, 
was dissected. If a second recording was made from the same animal, another 
segment of intestine was dissected, again starting distally. The mesentery was then 
pinned to the sylgard at right angle to the segment of intestine and the 
neurovascular bundle was dissected to allow isolation of the nerve bundle (Figure 
10a).  
 
 
 
2.3.2 Colonic nerve dissection 
For colonic nerve recordings, the segment of colon always included the anus. The 
neurovascular bundle was pinned flat at right angle to the colon and the lumbar 
splanchnic nerve was dissected between the inferior (IMG) and superior (SMG) 
mesenteric ganglia. The nerve naturally consists of 2 distinct and large bundles 
(intermesenteric nerves – IMN) and one of these was used for the recording (Figure 
10b).  
Figure 10 Schematic representation of the structures visible during the dissection of the (a) 
intestinal and (b) nerves. SMG: superior mesenteric ganglion, IMG: inferior mesenteric ganglion, IMN: 
inter-mesenteric nerve. 
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2.3.3 Experimental Protocols 
A recording of baseline activity over approximately 30 minutes was made before the 
recording chamber was superfused with a 20 ml volume of the test mediator. 
Because of the low spontaneous activity of colonic nerves, ramp distension to 80 
mmHg was undertaken at the beginning of the protocol to confirm the 
establishment of a recording. The specific protocol for each experiment is outlined in 
the relevant chapter.  
 
2.4 Data analysis 
A number of measures were used to analyse the data. 
 Peak response: nerve activity was expressed as mean frequency over 60 
seconds. Peak activity before and after application of the mediator was 
determined in spikes/second and the change in activity expressed as a mean 
± standard error of the mean (sem).  
 Response profile: nerve activity was expressed as mean frequency over 30 
seconds. The activity was then plotted against time starting at the time the 
mediator entered the recording chamber.  
 Duration of response: nerve activity was expressed as mean frequency over 
60 seconds. Figure 11 highlights the different time points along the response 
curve. Three main measures were used: time to start of response (= B – A), 
time to peak response (= C – A) and the duration of response (= G – A). In 
addition, three secondary measurements were made: time for the response 
to lose 20% (= D – C), 50% (= E - C) and 80% (= F - C) of its peak response.  
Comparisons were made between Nav1.9 +/+ and -/- mice using student’s t-test or 
two-way Analysis of variance (ANOVA) with bonferroni post hoc test as appropriate. 
Significance was set at p<0.05. 
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2.5 Single unit discrimination 
A consistent methodology was used to attempt discrimination of single units that 
constitute the multi-unit recordings. The analysis was performed using the “new 
wavemark” option in Spike 2. Templates were created when at least ten matching 
spikes were captured provided they were more frequent than one in 500 of the 
overall spike number. The spike width was set to a minimum of 32% of amplitude. 
Spikes were then matched to the template provided there was at least 75% points in 
common and there was no change in amplitude. The trigger thresholds were set to 
twice the background noise level. This analysis was applied to a subset of the colonic 
nerve recordings for five minutes before distension until 15 minutes after addition of 
0.3µM bradykinin.  
 
 
Figure 11 Schematic representation of the different time points along the response curve. A: 
time mediator entered the recording chamber, B: time when nerve activity increased above 
baseline, C: maximal firing rate after addition of the mediator, D: time when 20% of the 
response had been lost, E: time when 50% of the response had been lost, F: time when 80% 
of the response had been lost, G: time when nerve activity had returned to baseline.  
George Boundouki 
 
 
 61 
2.6 Chemicals 
All chemicals were purchased from Sigma Aldrich. Stock concentrations of bradykinin 
(10 mM) were dissolved in distilled water. Stock concentrations of indomethacin (30 
mM), nifedipine (100 mM) and capsaicin (10 mM) were dissolved in dimethyl 
sulfoxide (DMSO) and stock concentrations of atropine (100 mM) were dissolved in 
ethanol. Each aliquot was thawed immediately before use. Aliquots of human 
inflammatory supernatant were also thawed immediately before use.  
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3 
The role of Nav1.9 in the response of 
visceral afferents to chemical 
stimuli 
 
3.1 Aims 
 
The aims of the experiments discussed in this chapter are:  
1. To establish the preparation as a way of studying the role of Nav1.9 in 
afferent signalling 
2. To investigate the role of Nav1.9 in the response of visceral afferents to 
bradykinin, capsaicin and acetic acid when applied individually  
3. To investigate the role of Nav1.9 in the response of visceral afferents to a 
human inflammatory supernatant 
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3.2 Specific rationale  
 
Bradykinin and capsaicin increase afferent activity and have been used in somatic 
studies to investigate the role of Nav1.9 with attenuated responses demonstrated in 
Nav1.9 -/- mice. The evidence for a role for Nav1.9 in the response of visceral 
afferents to acetic acid is conflicting with a study in bladder afferents showing no 
role for Nav1.9 whereas a pan-visceral afferent study concluded that loss of Nav1.9 
increased the response of the afferents to acetic acid. No studies have used a human 
inflammatory supernatant to investigate the role of Nav1.9 in afferent signalling. The 
rationale for choosing these mediators is further discussed below.  
 
3.2.1 Bradykinin signalling 
Tissue damage leads to the activation of kallikreins which cleave kininogens to 
generate kinins. Kinins are a group of 9-11 amino acid peptides that include 
bradykinin and its active metabolite, des-Arg9-bradykinin (Couture et al. 2001). 
Bradykinin is an initial mediator of inflammation, induces pain and is a potent 
vasodilator. Its actions are mediated via two members of the rhodopsin family of 
GPCRs: B1 and B2. Both receptors have 7 helix transmembrane domains but are only 
36% identical at the amino acid level in human (Leeb-Lundberg et al. 2005). B2 is 
constitutively expressed whereas B1’s expression is induced as a result of tissue 
damage (Couture et al. 2001). Both receptors are widely expressed including in 
vascular, smooth muscle, epithelial and neuronal cells and fibroblasts (Leeb-
Lundberg et al. 2005). The receptors mainly signal through Gq and activate PLC that 
in turn cleaves PIP2 into DAG and IP3. DAG activates PKC while IP3 leads to the 
opening of Ca2+ channels and consequent release of Ca2+ into the cytoplasm (Leeb-
Lundberg et al. 2005). PKC modifies the function of other proteins, including 
transmembrane channels, e.g. Nav1.8, Nav1.9 and TRPV1 (Khasar et al. 1999; 
Premkumar and Ahern 2000; Vellani et al. 2001; Numazaki et al. 2002; Shin et al. 
2002; Baker 2005). Bradykinin also stimulates phospholipase A2 and D activation 
through G-protein mediated mechanisms. Although both receptors couple to similar 
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transduction pathways, there are differences in their signalling patterns: stimulation 
of the B2 receptor leads to rapid desensitization whereas B1 is desensitized to only a 
small degree (Leeb-Lundberg et al. 2005). This, in addition to post translational 
modification, leads to B2 signalling being transient while B1 signalling is more 
sustained (Mathis et al. 1996). This is consistent with the fact that B1 is induced by 
inflammation.  
 
Bradykinin exerts its effects in two ways: by directly stimulating afferents and by 
enhancing the effects of other stimuli, e.g. mechanical stimulation. This has been 
shown in both the somatic and visceral systems in rodent and man (Whalley et al. 
1987; Davis et al. 1996; Maubach and Grundy 1999; Brierley et al. 2005b). In 
addition, loss of the bradykinin receptors (either in knockout mice or by using 
antagonists) results in reduced somatic and visceral responses to inflammatory 
stimuli (Steranka et al. 1987; Heapy et al. 1993; Rupniak et al. 1997; Pesquero et al. 
2000). Recently, there has been interest in the interplay between bradykinin and 
Nav1.9 receptors. It is known that three quarters of Nav1.9 expressing somatic 
afferents also express B2 (Amaya et al. 2006). In addition, a somatic behavioural 
study has shown a significantly attenuated immediate response to intraplantar 
injection of bradykinin in Nav1.9 -/- mice (Amaya et al. 2006). The study also showed 
reduced thermal and mechanical hypersensitivity after application of bradykinin in 
Nav1.9 -/- mice. A parallel study in visceral afferents has not been conducted. Based 
on the above somatic study as well as patch clamp studies and extracellular 
multiunit recordings from visceral afferents in which bradykinin has been shown to 
activate neuronal cells, it is expected that the response of visceral afferents will be 
significantly reduced in Nav1.9 -/- mice.  
 
3.2.2 Transient receptor potential vanilloid-1 (TRPV1) signalling 
TRPV1 is a cation channel that is the receptor for capsaicin, protons and 
temperatures over 43 ˚C amongst many others and was first cloned by Caterina and 
colleagues in 1997. In common with other members of the TRP channel family, it 
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consists of six transmembrane domains with a pore between segments 5 and 6. The 
channel assembles as a tetramer and upon opening, allows inflow of calcium ions 
into the cell (Clapham et al. 2005). TRPV1 is mostly intracellular and upon 
depolarisation, is trafficked to the membrane where it is activated by agonists, 
desensitised and then recycled to the intracellular compartment ready for another 
cycle (Szallasi et al. 2006). It is preferentially located on small to medium diameter 
neurons which are known to be nociceptors (Caterina et al. 2000). The function of 
TRPV1 is enhanced by a number of signalling pathways activated by bradykinin, 
prostaglandins, ATP and other inflammatory mediators (Premkumar and Ahern 
2000; Vellani et al. 2001; Numazaki et al. 2002). In addition, acidic conditions lower 
the activation threshold of TRPV1 to other stimuli thus allowing the activation of the 
channel at normal body temperature (Tominaga et al. 1998). It can undergo 
desensitisation such that subsequent activation of the channel leads to reduced 
responses (Brierley et al. 2005a; Holzer 2008).  
 
TRPV1 is involved in the pathophysiology of inflammatory conditions. Its expression 
is increased in colorectal tissue from patients with an acute exacerbation of their IBD 
(Yiangou et al. 2001b) or rectal hypersensitivity (Chan et al. 2003; Akbar et al. 2008) 
while TRPV1 -/- mice lack the afferent hypersensitivity associated with inflammation 
(Caterina et al. 2000; Davis et al. 2000; Jones et al. 2005). In addition, DRG of adult 
mice that were subjected to acetic acid infusion as neonates revealed a significant 
increase in TRPV1 expression (Winston et al. 2007). An in vivo study of colorectal 
distension in rats showed that repeated distension resulted in a significant increase 
in the visceromotor response which was blocked by application of a TRPV1 
antagonist (Ravnefjord et al. 2009). In addition, a TRPV1 antagonist has been shown 
to reduce the thermal hyperalgesia expressed after injection of CFA into the hind 
paw of rats (Joshi et al. 2009). These studies highlight a significant role for TRPV1 in 
the sensitisation of both visceral and somatic afferents.  
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Over half of TRPV1 expressing neurons also express Nav1.9 (Amaya et al. 2000; 
Amaya et al. 2006). In addition, a somatic behavioural study has shown a 
significantly attenuated immediate response to intraplantar injection of capsaicin in 
Nav1.9 -/- mice (Amaya et al. 2006). The study also showed reduced mechanical 
hypersensitivity after capsaicin in Nav1.9 -/- mice. A parallel study in visceral 
afferents is lacking. Based on the above somatic study as well as patch clamp studies 
and extracellular multiunit recordings from visceral afferents in which capsaicin has 
been shown to activate neuronal cells, it is expected that the response of visceral 
afferents will be significantly reduced in Nav1.9 -/- mice.  
 
3.2.3 Acetic acid as a disease model 
Even though instillation of acetic acid has been used as a model for colonic 
inflammation for over 30 years (MacPherson and Pfeiffer 1978), its exact mechanism 
of action is not fully understood. Intraperitoneal acetic acid induces strong 
abdominal contractions that start within a few minutes of instillation and reach 
maximal frequency within 15 minutes (Martinez et al. 1999). It is possible that acetic 
acid exerts its effects by activation of membrane receptors; for example TRPV1 or 
acid sensing ion channel (ASIC) channels may be activated by the low pH. Indeed, 
there is evidence that antagonism of TRPV1 reduces the visceromotor response to 
colorectal distension caused by acetic acid infusion (Wiskur et al. 2010). The writhing 
test has been criticised because the intraperitoneal application of acetic acid causes 
activation of both somatic and visceral afferents and because the stimulus is never 
naturally encountered by the animal. Infusion of acetic acid into the bladder causes a 
reduction in maximal filling and voided volumes in association with an increase in 
frequency and amplitude of bladder contractions reflecting a sensitised system 
(Ritter et al. 2009).  
 
Two recent studies have investigated the role of Nav1.9 in the response of the 
viscera to acetic acid. An in vivo study of mouse bladder concluded that there was no 
role for Nav1.9 in the pathogenesis of the effects of acetic acid (Ritter et al. 2009) 
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while a study investigating the number of abdominal contractions after 
intraperitoneal instillation of acetic acid showed a doubling in the number of writhes 
in Nav1.9 -/- mice (Leo et al. 2010). The latter finding is not consistent with other 
studies which have shown an analgesic effect to knock-out of Nav1.9. This 
contradiction and the differing results between the two acetic acid studies may be 
due to the different doses used (0.25% in the bladder study vs. 1% in the colonic 
study), to the relative contribution of Nav1.9 to each system or to differences 
between mouse strains.  
 
3.2.4 Role of an inflammatory soup 
Many studies have examined the effect of inflammatory mediators on afferent 
signalling with most investigating each mediator in isolation. In vivo, inflammatory 
reactions lead to the release or recruitment of a large number of mediators. Hence, 
studying mediators in isolation, in vitro, is a poor model for the pathophysiological 
process occurring in vivo. A number of studies have shown that application of an 
‘inflammatory soup’ consisting of a number of mediators leads to more robust 
activation of visceral afferents (Alessandri-Haber et al. 2006; Maingret et al. 2008). 
Three studies have created human tissue supernatants from colonic biopsy samples 
from patients diagnosed with IBS and studied their effect on nerve activity (Barbara 
et al. 2007; Cenac et al. 2007; Buhner et al. 2009). No group has used acutely 
inflamed full thickness intestinal tissue to create an inflammatory supernatant.  
 
Appendicitis is one of the most common reasons for admission to a surgical ward 
with over 45,000 appendicectomies performed every year (DoH 2012). The diagnosis 
is usually made on clinical history and examination along with the results of routine 
biochemical investigations. In some instances, imaging studies are used to inform the 
decision making process. Three groups have attempted to analyse the inflammatory 
mediators released during appendicitis. At the beginning of the operation, the 
groups either aspirated peritoneal fluid (Dalal et al. 2005) or instilled 0.9% saline into 
the peritoneal cavity and then aspirated it 1 minute later (Rivera-Chavez et al. 2003; 
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Yamamoto et al. 2005). The cytokine levels in the fluid were measured but were 
highly variable between the three studies with one group reporting detectable 
cytokines in only 50% of patients (Yamamoto et al. 2005). Indeed, a technique which 
relies on instillation of a saline solution into the peritoneal cavity and its aspiration 
after 60 seconds is unlikely to be representative of the cytokine environment in the 
inflamed appendix. No attempt was made to measure cytokine levels in the 
appendicular tissue itself which would be a more accurate reflection of the 
environment that the visceral afferents experience. Based on somatic studies using 
individual mediators and patch clamp studies using individual mediators as well as 
combinations of mediators, it is expected that the response of visceral afferents to a 
human inflammatory supernatant will be significantly reduced in Nav1.9 -/- mice.  
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3.3 Experimental protocols 
 
3.3.1 Bradykinin 
The effect of bradykinin on nerve activity was investigated in both intestinal and 
colonic preparations. In intestinal preparations, a single 3 µM dose was used. In 
colonic preparations, consecutive applications of 0.3 µM, 1 µM and 3 µM were 
superfused 60 minutes apart. The nerve activity had returned to baseline before the 
next dose was applied.  
3.3.1.1 Intestinal recordings 
 
 
3.3.1.2 Colonic recordings 
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3.3.2 Capsaicin 
The effect of 1 µM capsaicin was investigated in both intestinal and colonic 
preparations. In the initial intestinal preparations, the capsaicin was applied after 
other mediators. Further experiments were performed where capsaicin was the only 
mediator applied and there was no difference in the magnitude of response so the 
data was analysed as one group. In colonic preparations, capsaicin was the only 
mediator applied to the preparation. 
 
3.3.1.1 Intestinal recordings 
 
 
3.3.1.2 Colonic recordings 
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3.3.3 Acetic acid 
The effect of acetic acid was investigated in colonic preparations only. Consecutive 
applications of 0.01%, 0.1%, 0.3% and 1% acetic acid were superfused 60 minutes 
apart. The nerve activity had returned to baseline before the next dose was applied.  
 
 
3.3.4 Human inflammatory supernatant 
The effect of human supernatants was investigated in colonic preparations only. A 
single dose of the supernatant was applied to each preparation. Control 
supernatants were tested in Nav1.9 +/+ mice only whereas inflammatory 
supernatants were tested in both Nav1.9 +/+ and -/- mice. In contrast to the other 
stimuli, the volume of supernatant superfused varied between 10 and 15 ml due to 
the natural variability in the size of the appendices.  
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3.4 Results  
 
3.4.1 Baseline activity 
 
Baseline firing was significantly lower in intestinal and colonic nerves from Nav1.9 -/- 
compared to +/+ mice (intestinal: Nav1.9 +/+ 40.4 ± 4.7 vs. Nav1.9 -/- 16.3 ± 2.2 Hz; 
n=13; p<0.001. Colonic: Nav1.9 +/+ 3.1 ± 0.6 vs. Nav1.9 -/- 1.1 ± 0.2 Hz; n=26-34; 
p<0.05. Figures 12a and 12b). 
 
In addition, the baseline firing of colonic nerves was significantly lower than 
intestinal nerves in both Nav1.9 +/+ and -/- mice (Nav1.9 +/+: intestinal 40.4 ± 4.7 vs. 
colonic 3.1 ± 0.6 Hz; n=13-34; p<0.001. Nav1.9 -/-: intestinal 16.3 ± 2.2 vs. colonic 1.1 
± 0.2 Hz; n=13-26; p<0.001. Figure 12c). 
 
Single unit analysis of a subset of the colonic recordings revealed a higher number of 
units per recording from Nav1.9 +/+ compared to -/- mice (Nav1.9 +/+ 7.2 (range 5-
11) vs. Nav1.9 -/- 2.8 (range 1-5) units; n=5-6). A similar proportion of these single 
units were active prior to stimulation across Nav1.9 +/+ and -/- recordings (Nav1.9 
+/+ 16/36 (44.4%) vs. Nav1.9 -/- 6/17 (35.3%) units; n=5-6).  
 
George Boundouki 
 
 
 73 
  
Figure 12 Baseline nerve activity in Nav1.9 +/+ and -/- mice. (a) histogram comparing the baseline 
activity of intestinal nerves (b) histogram comparing the baseline activity of colonic nerves (c) 
histogram comparing the baseline activity of intestinal and colonic nerves. * p < 0.05 *** p < 0.001. 
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3.4.2 Response to bradykinin 
 
Intestinal nerves were subjected to a single application of 3 µM bradykinin. The peak 
response of nerves from Nav1.9 -/- mice was significantly reduced as compared to 
+/+ mice (Nav1.9 +/+ 73.6 ± 7.3 vs. Nav1.9 -/- 22.1 ± 4.5 Hz; n=5-6; p<0.001. Figure 
13). Although there was a significant difference between the response profiles (two-
way ANOVA p<0.001. Figure 13c), the difference in specific durations was not 
significant (Figure 14).  
 
Colonic nerve preparations were subjected to consecutive applications of 0.3 µM,     
1 µM and 3 µM bradykinin 60 minutes apart. The response was almost completely 
abolished in Nav1.9 -/- mice (0.3 µM: Nav1.9 +/+ 7.8 ± 1.9 vs. Nav1.9 -/- 0.6 ± 0.3 Hz; 
p<0.01. 1 µM: Nav1.9 +/+ 6.4 ± 1.7 vs. Nav1.9 -/- 0.4 ± 0.2 Hz; p<0.01. 3 µM: Nav1.9 
+/+ 7.8 ± 2.6 vs. Nav1.9 -/- 0.4 ± 0.2 Hz; p<0.05; n=6. Figure 15).  
Single unit analysis of the response of colonic afferents to 0.3µM bradykinin revealed 
that in Nav1.9 +/+ recordings, the firing rate of 34 of the 36 (94.4%) units increased 
after application of 0.3µM bradykinin. In recordings from Nav1.9 -/- mice, the firing 
rate of only three out of 17 (17.6%) units increased after 0.3µM bradykinin. The 
number of action potentials over time increased by 958% in Nav1.9 +/+ mice 
compared to a 628% increase in Nav1.9 -/- mice. Of the Nav1.9 +/+ units which 
experienced an increase in firing in response to 0.3µM bradykinin, 14 had not 
responded to intra luminal distension and five were not active prior to application of 
the bradykinin. Neither of these phenomena were observed in Nav1.9 -/- recordings.  
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Figure 13 The effect of 3 µM bradykinin on intestinal nerve activity. Representative raw trace 
recordings and response rate (mean frequency over 60 seconds) from (a) Nav1.9 +/+ and (b) Nav1.9 -/- 
mice. The arrows indicate the addition of bradykinin. Below the raw trace, 1 second extracts are 
shown before and after the addition of bradykinin. (c) Average profile of response (two-way ANOVA 
p<0.001). (d) Histogram comparing the peak response. *** p < 0.001 
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Figure 14 The duration of the intestinal response to 3 µM bradykinin. (a) time from bradykinin 
entering the bath to nerve activity rising above baseline (Nav1.9 +/+ 51.5 ± 15.1 vs. Nav1.9 -/- 51.0 ± 
6.0 seconds; n=4-5; p=0.97). (b) time from bradykinin entering the bath to peak response (Nav1.9 +/+ 
154.5 ± 28.9 vs. Nav1.9 -/- 130.8 ± 17.3 seconds; n=4-5; p=0.48). (c) time from peak response to 80% 
of the peak response (Nav1.9 +/+ 48.3 ± 11.4 vs. Nav1.9 -/- 29.2 ± 8.5 seconds; n=4-5; p=0.21). (d) time 
from peak response to 50% of the peak response (Nav1.9 +/+ 194.7 ± 40.8 vs. Nav1.9 -/- 113.2 ± 35.1 
seconds; n=3-5; p=0.19). (e) time from peak response to 20% of the peak response (Nav1.9 +/+ 412.0 
± 51.9 vs. Nav1.9 -/- 182.3 ± 117.9 seconds; n=3; p=0.15). (f) time from bradykinin entering the bath to 
nerve activity returning to baseline (Nav1.9 +/+ 1727.0 ± 845.0 vs. Nav1.9 -/- 809.3 ± 483.1 seconds; 
n=2-3; p=0.38). 
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Figure 15 The effect of bradykinin on colonic nerve activity. Representative raw trace recordings and 
response rate (mean frequency over 60 seconds) from (a) Nav1.9 +/+ and (b) Nav1.9 -/- mice after 
addition of 3 µM bradykinin. The arrows indicate the addition of bradykinin. Below the raw trace, 2 
second extracts are shown before and after the addition of bradykinin. (c) Average profile of response 
to 3 µM bradykinin (two-way ANOVA p<0.001). (d) Histogram comparing the peak response to three 
concentrations of bradykinin. * p < 0.05 ** p < 0.01 
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3.4.3 Response to capsaicin 
 
A single application of 1 µM capsaicin was applied to both intestinal and colonic 
nerves. In intestinal recordings, the peak response (Nav1.9 +/+ 39.0 ± 5.2 vs. Nav1.9    
-/- 17.8 ± 3.2 Hz; n=10-12; p<0.01. Figure 16) was followed (in 9/10 Nav1.9 +/+ and 
10/12 Nav1.9 -/- recordings) by inhibition of the nerve activity (Nav1.9 +/+ 28.5 ± 3.9 
vs. Nav1.9 -/- 14.7 ± 3.2 Hz; n=9-10; p<0.01). The difference between the response 
profiles was significant (two-way ANOVA p<0.01. Figure 16c). There was a trend for a 
longer time to reach peak response and a less steep decline in firing in the Nav1.9 -/- 
mice but this was not significant (figure 17).  
 
The peak response of colonic nerves was also significantly lower in Nav1.9 -/- mice 
(Nav1.9 +/+ 8.2 ± 1.1 vs. Nav1.9 -/- 3.9 ± 0.9 Hz; n=7; p<0.01. Figure 18). Due to the 
low baseline firing of colonic nerves, there was no appreciable inhibition of firing 
after the initial response. The time taken to reach the peak response was 
significantly shorter in Nav1.9 -/- mice (Nav1.9 +/+ 179.1 ± 24.4 vs. Nav1.9 -/- 103.6 ± 
9.6 seconds; n=7; p<0.05. Figure 19b). 
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Figure 16 The effect of 1 µM capsaicin on intestinal nerve activity. Representative raw trace 
recordings and response rate (mean frequency over 60 seconds) from (a) Nav1.9 +/+ and (b) Nav1.9 -/- 
mice. The arrows indicate the addition of capsaicin. Below the raw trace, 1 second extracts are shown 
before and after the addition of capsaicin. (c) Average profile of response (two-way ANOVA p<0.01). 
(d) Histogram comparing the peak response ** p < 0.01 
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Figure 17 The duration of the intestinal response to 1 µM capsaicin. (a) time from capsaicin entering 
the bath to nerve activity rising above baseline (Nav1.9 +/+ 124.4 ± 27.2 vs. Nav1.9 -/- 95.6 ± 23.9 
seconds; n=10-11; p=0.43). (b) time from capsaicin entering the bath to peak response (Nav1.9 +/+ 
218.8 ± 29.2 vs. Nav1.9 -/- 231.2 ± 33.4 seconds; n=10-11; p=0.78). (c) time from peak response to 
80% of the peak response (Nav1.9 +/+ 24.5 ± 7.1 vs. Nav1.9 -/- 27.0 ± 4.5 seconds; n=10-11; p=0.77). 
(d) time from peak response to 50% of the peak response (Nav1.9 +/+ 48.3 ± 11.6 vs. Nav1.9 -/- 80.3 ± 
17.1 seconds; n=10-11; p=0.15). (e) time from peak response to 20% of the peak response (Nav1.9 +/+ 
87.7 ± 20.2 vs. Nav1.9 -/- 174.2 ± 40.3 seconds; n=10-11; p=0.08). (f) time from capsaicin entering the 
bath to nerve activity returning to baseline (Nav1.9 +/+ 365.1 ± 48.0 vs. Nav1.9 -/- 343.8 ± 65.2 
seconds; n=9-10; p=0.79). 
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Figure 18 The effect of 1 µM capsaicin on colonic nerve activity. Representative raw trace recordings 
and response rate (mean frequency over 60 seconds) from (a) Nav1.9 +/+ and (b) Nav1.9 -/- mice. The 
arrows indicate the addition of capsaicin. Below the raw trace, 2 second extracts are shown before 
and after the addition of capsaicin. (c) Average profile of response (two-way ANOVA p<0.001). (d) 
Histogram comparing the peak response. ** p < 0.01 
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Figure 19 The duration of the colonic response to 1 µM capsaicin. (a) time from capsaicin entering 
the bath to nerve activity rising above baseline (Nav1.9 +/+ 53.0 ± 6.4 vs. Nav1.9 -/- 52.1 ± 10.7 
seconds; n=7; p=0.95). (b) time from capsaicin entering the bath to peak response (Nav1.9 +/+ 179.1 ± 
24.4 vs. Nav1.9 -/- 103.6 ± 9.6 seconds; n=7; p<0.05). (c) time from peak response to 80% of the peak 
response (Nav1.9 +/+ 29.6 ± 4.0 vs. Nav1.9 -/- 18.7 ± 4.0 seconds; n=7; p=0.08). (d) time from peak 
response to 50% of the peak response (Nav1.9 +/+ 62.6 ± 14.4 vs. Nav1.9 -/- 54.0 ± 12.0 seconds; n=7; 
p=0.66). (e) time from peak response to 20% of the peak response (Nav1.9 +/+ 111.0 ± 28.6 vs. Nav1.9 
-/- 98.9 ± 19.9 seconds; n=7; p=0.73). (f) time from capsaicin entering the bath to nerve activity 
returning to baseline (Nav1.9 +/+ 354.9 ± 60.5 vs. Nav1.9 -/- 279.6 ± 42.2 seconds; n=7; p=0.33). * p < 
0.05 
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3.4.4 Response to acetic acid 
 
The response of colonic nerves to acetic acid was investigated by consecutive 
applications of 0.01%, 0.1%, 0.3% and 1% acetic acid. The response to 0.01% acetic 
acid was minimal in both groups (Nav1.9 +/+ 0.4 ± 0.3 vs. Nav1.9 -/- 0.0 ± 0.0 Hz; n=6; 
p=0.29. Figure 20d).  
 
There was a trend for the peak response to 0.1% acetic acid to be lower in Nav1.9 -/- 
mice but this was not significant (Nav1.9 +/+ 8.2 ± 2.9 vs. Nav1.9 -/- 4.7 ± 2.2 Hz; n=6; 
p=0.35. Figure 20d). However, the overall response was significantly different 
between the two groups (two-way ANOVA p<0.01. Figure 20c). There were no 
significant differences in the sub-durations of the response to 0.1% acetic acid 
(Figure 21). 
 
The response to 0.3% acetic acid was more complicated. All nerves exhibited a rise in 
activity in response to the acetic acid (Nav1.9 +/+ 19.7 ± 6.3 vs. Nav1.9 -/- 13.8 ± 3.4 
Hz; n=6; p=0.43. Figure 20d). Four out of six nerves from Nav1.9 -/- and five out of six 
nerves from Nav1.9 +/+ mice exhibited a second smaller peak (Nav1.9 +/+ 10.0 ± 3.8 
vs. Nav1.9 -/- 4.1 ± 2.0 Hz; n=4-5; p=0.24. Figure 22d). The time taken to reach this 
second peak was significantly longer in Nav1.9 -/- mice (Nav1.9 +/+ 562.6 ± 37.8 vs. 
Nav1.9 -/- 727.3 ± 15.3 seconds; n=4-5; p<0.01. Figure 23d).  
 
The response to 1% acetic acid was very short. Interestingly, in contrast to the lower 
doses tested, the peak response of Nav1.9 -/- mice was higher than +/+ mice but this 
was not significant (Nav1.9 +/+ 10.9 ± 3.3 vs. Nav1.9 -/- 13.9 ± 4.6 Hz; n=6; p=0.60. 
Figure 20d). This was followed by total cessation of nerve activity in both groups. The 
response profiles of the four concentrations of acetic acid are shown in Figure 24. 
The profiles at 0.1% and 0.3% were significantly different between the groups (two-
way ANOVA: 0.1% p<0.01, 0.3% p<0.001).   
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Figure 20 The effect of acetic acid on colonic nerve activity. Representative raw trace recordings and 
response rate (mean frequency over 60 seconds) from (a) Nav1.9 +/+ and (b) Nav1.9 -/- mice in 
response to 0.1% acetic acid. The arrows indicate the addition of acetic acid. Below the raw trace, 2 
second extracts are shown before and after the addition of acetic acid. (c) Average profile of response 
to 0.1% acetic acid (two-way ANOVA p<0.01). (d) Histogram comparing the peak response to four 
concentrations of acetic acid. 
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Figure 21 The duration of the colonic response to 0.1% acetic acid. (a) time from acetic acid entering 
the bath to nerve activity rising above baseline (Nav1.9 +/+ 111.3 ± 20.2 vs. Nav1.9 -/- 145.0 ± 39.4 
seconds; n=5-6; p=0.44). (b) time from acetic acid entering the bath to peak response (Nav1.9 +/+ 
330.2 ± 16.7 vs. Nav1.9 -/- 327.0 ± 8.0 seconds; n=5-6; p=0.88. (c) time from peak response to 80% of 
the peak response (Nav1.9 +/+ 77.7 ± 15.8 vs. Nav1.9 -/- 38.6 ± 5.2 seconds; n=5-6; p=0.06). (d) time 
from peak response to 50% of the peak response (Nav1.9 +/+ 196.5 ± 25.3 vs. Nav1.9 -/- 164.0 ± 35.0 
seconds; n=5-6; p=0.46). (e) time from peak response to 20% of the peak response (Nav1.9 +/+ 336.8 
± 53.4 vs. Nav1.9 -/- 331.8 ± 71.49 seconds; n=5-6; p=0.96). (f) time from acetic acid entering the bath 
to nerve activity returning to baseline (Nav1.9 +/+ 941.2 ± 113.5 vs. Nav1.9 -/- 858.0 ± 89.1 seconds; 
n=5-6; p=0.59).  
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Figure 22 The effect of 0.3% acetic acid on colonic nerve activity. Representative raw trace 
recordings and response rate (mean frequency over 60 seconds) from (a) Nav1.9 +/+ and (b) Nav1.9 -/- 
mice in response to acetic acid. The arrows indicate the addition of acetic acid. Below the raw trace, 2 
second extracts are shown before and after the addition of acetic acid. (c) Average profile of response 
to 0.3% acetic acid (two-way ANOVA p<0.001). (d) Histogram comparing the two peak responses. 
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Figure 23 The duration of the colonic response to 0.3% acetic acid. (a) time from acetic acid entering 
the bath to nerve activity rising above baseline (Nav1.9 +/+ 68.2 ± 8.2 vs. Nav1.9 -/- 66.2 ± 19.3 
seconds; n=6; p=0.93). (b) time from acetic acid entering the bath to 1st peak response (Nav1.9 +/+ 
203.3 ± 10.3 vs. Nav1.9 -/- 216.0 ± 16.6 seconds; n=6; p=0.53). (c) duration of the 1st response (Nav1.9 
+/+ 331.7 ± 30.0 vs. Nav1.9 -/- 567.8 ± 147.5 seconds; n=6; p=0.15). (d) time from acetic acid entering 
the bath to 2nd peak response (Nav1.9 +/+ 562.6 ± 37.8 vs. Nav1.9 -/- 727.3 ± 15.3 seconds; n=4-5; 
p<0.01). (e) duration of the 2nd response (Nav1.9 +/+ 821.4 ± 182.2 vs. Nav1.9 -/- 795.0 ± 119.3 
seconds; n=4-5; p=0.91). (f) time from acetic acid entering the bath to nerve activity returning to 
baseline (Nav1.9 +/+ 1016.0 ± 227.6 vs. Nav1.9 -/- 1098.0 ± 89.0 seconds; n=6; p=0.75). ** p < 0.01 
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Figure 24 The effect of acetic acid on colonic nerve activity. Average profile of response to (a) 0.01% 
(two-way ANOVA p=0.14), (b) 0.1% (two-way ANOVA p<0.01), (c) 0.3% (two-way ANOVA p<0.001) and 
(d) 1% (two-way ANOVA p=0.39) acetic acid. 
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3.4.5 Response to human inflammatory supernatants 
 
The response of human supernatant on nerve activity was tested in colonic 
preparations only. In Nav1.9 +/+ mice, application of the control supernatant caused 
a small increase in nerve activity. This was significantly lower than that caused by the 
inflammatory supernatant (control supernatant 0.6 ± 0.1 vs. inflammatory 
supernatant 1.4 ± 0.1 Hz; n=5; p<0.001. Figure 25). Application of the inflammatory 
supernatant to colonic nerves from Nav1.9 -/- mice caused an increase in nerve 
activity significantly lower than that in Nav1.9 +/+ mice (Nav1.9 +/+ 1.4 ± 0.1 vs. 
Nav1.9 -/- 0.8 ± 0.1 Hz; n=3-5; p<0.05. Figure 26). The volume of inflammatory 
supernatant generated from the appendices of two patients was sufficient to allow 
multiple tests. Hence, each supernatant was tested on a nerve from Nav1.9 +/+ and   
-/- mice.  Although the number of tests (2) does not allow meaningful statistical 
comparison, the increase in nerve activity in response to application of the 
supernatant was higher in nerves from Nav1.9 +/+ than Nav1.9 -/- mice (Nav1.9 +/+ 
1.5 ± 0.4 vs. Nav1.9 -/- 0.8 ± 0.3 Hz; n=2).   
 
The profiles of the response to the inflammatory mediators were not significantly 
different between the two groups (two-way ANOVA p=0.05. Figure 26c). There was a 
trend towards a shorter response in Nav1.9 -/- mice but this was also not significant 
(Figure 27).  
 
The cytokine content of inflammatory and control supernatants was assayed. There 
was a trend for higher concentrations of cytokines in the inflammatory supernatants 
but this did not reach significance (IL-1β: control 6.0 ± 2.9 vs. inflamed 20.9 ± 9.3 
pg/ml; p=0.21. IL-6: control 248.9 ± 71.2 vs. inflamed 356.1 ± 157.6 pg/ml; p=0.59. 
GM-CSF: control 14.4 ± 4.8 vs. inflamed 28.2 ± 9.8 pg/ml; p=0.28. TNF-α: control 2.3 
± 0.5 vs. inflamed 3.0 ± 1.0 pg/ml; p=0.59. IL-8: control 178.7 ± 129.5 vs. inflamed 
1197.0 ± 502.8 pg/ml; p=0.12; n=4-5. Figure 28). 
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Table xxxx shows patient demographics and white blood cell counts. The difference 
in ages between patients who donated normal appendices and those who donated 
inflamed appendices is a reflection of their disease aetiology as patients in the 
former group had their surgery for bowel cancer. The white blood cell count of the 
patients who had inflamed appendices trended higher than those who had normal 
appendices (normal 6.9 ± 1.0 vs. inflamed 11.4 ± 1.8 x103 cells/µl; n=5-6; p=0.06. 
Figure 29). When the white cell count of the patients who donated inflamed 
supernatants were analysed based on whether the supernatants were used on 
nerves from Nav1.9 +/+ or -/- mice, there was no difference between the groups 
(Nav1.9 +/+ 11.0 ± 2.1 vs. Nav1.9 -/- 12.6 ± 0.9 x103 cells/µl; n=3-5; p=0.61. Figure 29). 
C-reactive protein levels were only available from some patients who had inflamed 
appendices (it is not consistently checked in suspected acute appendicitis and not 
before planned cancer surgery). Therefore, no comparison is possible between the 
normal and inflamed groups. In addition, no information on patient co-morbidities 
was collected at the time of collection of samples.  
 
 Normal 
supernatant on 
Nav1.9 +/+ nerves 
Inflamed 
supernatant on 
Nav1.9 +/+ nerves 
Inflamed 
supernatant on 
Nav1.9 -/- nerves 
Gender M:F 2:3 3:2 1:2 
Age (yrs) 64 32 43 
White cell count 
(cells/µl) 
6.9 11.0 12.6 
Table 2 Age, gender and white cell count of patients who donated appendices. 
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Figure 25 The effect of human supernatant on colonic nerve activity. * p < 0.05 *** p < 0.001 
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Figure 26 The effect of human supernatant on colonic nerve activity. Representative raw trace 
recordings and response rate (mean frequency over 60 seconds) from (a) Nav1.9 +/+ and (b) Nav1.9 -/- 
mice after addition of human supernatant. The arrows indicate the addition of supernatant. Below 
the raw trace, 2 second extracts are shown before and after the addition of supernatant. (c) Average 
profile of response (two-way ANOVA p=0.05). (d) Histogram comparing the peak response. * p < 0.05 
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Figure 27 The duration of the colonic nerve response to human supernatant. (a) time from 
supernatant entering the bath to nerve activity rising above baseline (Nav1.9 +/+ 288.2 ± 91.5 vs. 
Nav1.9 -/- 208.3 ± 52.0 seconds; n=3-5; p=0.55). (b) time from supernatant entering the bath to peak 
response (Nav1.9 +/+ 499.6 ± 139.2 vs. Nav1.9 -/- 304.3 ± 55.5 seconds; n=3-5; p=0.34). (c) time from 
peak response to 80% of the peak response (Nav1.9 +/+ 28.6 ± 6.1 vs. Nav1.9 -/- 11.0 ± 2.0 seconds; 
n=3-5; p=0.08). (d) time from peak response to 50% of the peak response (Nav1.9 +/+ 71.0 ± 20.6 vs. 
Nav1.9 -/- 35.7 ± 5.5 seconds; n=3-5; p=0.25). (e) time from peak response to 20% of the peak 
response (Nav1.9 +/+ 346.5 ± 133.2 vs. Nav1.9 -/- 47.7 ± 8.4 seconds; n=3-4; p=0.12). (f) time from 
supernatant entering the bath to nerve activity returning to baseline (Nav1.9 +/+ 1147.0 ± 305.8 vs. 
Nav1.9 -/- 754.0 ± 224.2 seconds; n=3-4; p=0.38).  
George Boundouki 
 
 
 94 
 
 
 
  
Figure 28 Cytokine content of inflammatory and control supernatants. 
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Figure 29 The white blood cell count of patients who provided appendix supernatants. 
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3.5 Specific discussion 
 
3.5.1 The role of Nav1.9 in the spontaneous activity of visceral afferents 
The data generated demonstrate an important role for Nav1.9 in the level of 
spontaneous visceral afferent activity. In both intestinal and colonic recordings, the 
level of spontaneous activity was approximately 60% lower in Nav1.9 -/- compared to 
+/+ mice. In addition, the spontaneous activity of colonic afferents was less than 10% 
of the activity of intestinal afferents. This difference was seen across wild type and 
knockout mice. Off-line single unit analysis of a subset of the colonic afferent 
recordings revealed a greater number of units per recording of nerve activity in 
Nav1.9 +/+ compared to -/- mice. The proportion of these units that were 
‘spontaneously’ active was similar across both genotypes.  
 
Nav1.9 expresses a unique slow, persistent, tetrodotoxin resistant current (Dib-Hajj 
et al. 1998). It is known to become activated at a threshold which is close to the 
resting membrane potential and lower than those of other voltage gated sodium 
channels. Thus, Nav1.9 is thought to contribute to setting the membrane potential 
(Herzog et al. 2001). Knock-out of Nav1.9 leads to loss of this unique current which, 
when activated, ‘nudges up’ the membrane potential closer to the threshold 
necessary for action potential generation. Loss of Nav1.9 therefore leads to an 
increase in the stimulus necessary for action potential generation. This is not always 
present in the ‘resting’ state which may explain the lower ‘spontaneous’ activity in    
-/- mice. In the single unit analysis of multi-unit colonic recordings, the number of 
units per recording was approximately 60% lower in Nav1.9 -/- compared to Nav1.9 
+/+ mice. This corresponds to the drop in recoded overall activity. This suggests that 
it maybe the reduced number of units rather than less active units that contribute to 
the lower activity noted in recordings from Nav1.9 -/- mice. Unfortunately, because 
of the low absolute number of ‘spontaneously’ active units in recordings from Nav1.9 
-/- mice, it was not possible to compare the activity of the single units between the 
genotypes.   
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A number of studies have reported that a majority of splanchnic afferents are silent 
at rest (Brierley et al. 2004; Brierley et al. 2005b; Feng and Gebhart 2011) while 
intestinal nerve recordings demonstrate significant spontaneous activity (Brunsden 
and Grundy 1999; Maubach and Grundy 1999). Data presented here confirm that the 
spontaneous activity of intestinal afferents is significantly higher than that of colonic 
afferents. There are a number of possible explanations. Firstly, it could be due to a 
difference in the number of fibres in the mesenteric as compared to the IMN nerve 
bundles from which the recordings are made. Secondly, mesenteric bundles contain 
vagal and spinal afferents while IMN bundles consist of only spinal afferents. Vagal 
afferents are activated at low threshold which may explain the higher ‘spontaneous’ 
activity of the mesenteric bundles. Alternatively, two scenarios may explain the 
difference between intestinal and colonic afferent: either a similar number of units 
are spontaneously active in both pathways but the splanchnic units have much lower 
spontaneous activity or secondly that significantly fewer units are spontaneously 
active in the splanchnic pathway. Unfortunately, the nature of extracellular, multi-
unit recordings does not permit the investigation of these theories. Due to the high 
activity of intestinal afferents, off-line single unit analysis of the data does not 
provide meaningful data. Based on single unit data from other groups suggesting 
that the majority of splanchnic afferents are inherently silent at rest, it seems that 
the second scenario is the more likely explanation for the lower spontaneous activity 
demonstrated by my multi-unit recordings.  
 
3.5.2 The role of Nav1.9 in the activation of visceral afferents by bradykinin 
The data generated demonstrate an important role for Nav1.9 in the response of 
visceral afferents to bradykinin. The response of colonic afferents to bradykinin was 
reduced by 90% in Nav1.9 -/- mice suggesting that Nav1.9 plays a crucial role in the 
bradykinin signalling pathway in spinal afferents. The reduction in the response of 
intestinal afferents was 70% which, while lower than in colonic afferents, implies 
that Nav1.9 plays a key role in bradykinin signalling in both vagal and spinal visceral 
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afferents. Single unit analysis of the response of colonic afferents to 0.3µM 
bradykinin revealed that a much higher proportion of Nav1.9 +/+ units responded to 
the bradykinin as compared to Nav1.9 -/- units. The increase in activity of these units 
was also greater in Nav1.9 +/+ compared to Nav1.9 -/- mice. In addition, a proportion 
of the Nav1.9 +/+ units that responded to bradykinin did not respond to intra-luminal 
distension, a property not observed in Nav1.9 -/- mice.  
This data is consistent with that from a behavioural study in somatic afferents 
investigating the immediate paw licking response caused by intraplantar injection of 
bradykinin. Amaya et al investigated this response in Nav1.9 +/+ and -/- mice. 
Injection of 300 ng bradykinin caused an immediate response in both groups of mice 
but the response in Nav1.9 -/- mice was reduced by over 80% (Amaya et al. 2006). In 
addition, Nav1.9 -/- mice also exhibited significantly reduced mechanical and thermal 
hypersensitivity. The data from the behavioural study are consistent with the 
findings reported here with regards to the magnitude of the effect of eliminating 
Nav1.9 from spinal afferents. 
 
Bradykinin mediates its effects though activation of PKC amongst other mechanisms 
(Leeb-Lundberg et al. 2005). PKC has been shown to upregulate the Nav1.9 current 
(Baker 2005) providing a possible mechanism for bradykinin to enhance the Nav1.9 
current. In addition to Nav1.9, other ion channels have been implicated in the 
bradykinin signalling pathway, e.g. TRPV1 and TRPA1 (Premkumar and Ahern 2000; 
Bandell et al. 2004). While this has not been investigated as part of this thesis, the 
substantial contribution by Nav1.9 to the bradykinin signalling pathway 
demonstrated by these data implies that other contributors have relatively minor 
roles. Indeed, the response of splanchnic serosal afferents to bradykinin was not 
significantly different between TRPA1 +/+ and -/- mice (Brierley et al. 2009). 
Interestingly, the mechanical hypersensitivity to bradykinin was reduced in TRPA1 -/- 
mice. The Amaya study also demonstrated reduced mechanical hypersensitivity in 
Nav1.9 -/- mice implying that, while the direct response to bradykinin is closely 
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related to Nav1.9, its secondary sensitisation effects occur via modulation of a 
number of ion channels. 
 
While there are no data quantifying expression of bradykinin receptors in visceral 
afferents, data from non retrogradely-labelled DRG demonstrate bradykinin labelling 
in 43 - 52% of the total cultured DRG (Segond von Banchet et al. 1996; Petersen et al. 
1998). Brierley et al showed that 50 - 60% of mechanosensitive serosal lumbar 
splanchnic afferents responded to application of bradykinin (Brierley et al. 2005b; 
Brierley et al. 2009). In addition, a number of mechanically insensitive afferents also 
responded to bradykinin although it was not possible to calculate their proportion of 
the total mechanically insensitive population as they were found incidentally rather 
than being systematically searched for (Brierley et al. 2005b). A study which 
systematically investigated the whole lumbar splanchnic afferent population using 
electrical stimulation found that a third were mechanically insensitive (Feng and 
Gebhart 2011). Only 12% of these mechanically insensitive afferents responded to an 
inflammatory soup containing bradykinin, serotonin, histamine and PGE2. The 
Brierley study only investigated serosal afferents but if the results are extrapolated 
to all afferent classes then it can be assumed that approximately half of lumbar 
splanchnic afferents are responsive to bradykinin. Amalgamating these results with 
those of Feng and Gebhart suggests that approximately 40% of all lumbar splanchnic 
afferents respond to bradykinin and so must express receptors for bradykinin. This 
figure is consistent with that found in the somatic system (Petersen et al. 1998).  
 
No studies have explored the distribution of Nav1.9 in visceral afferents. Data from 
the somatic system show that Nav1.9 is expressed on 35 – 61% of L4-5 DRG and 
approximately 70% of L6 and S1 DRG (Amaya et al. 2000; Decosterd et al. 2002; 
Black et al. 2003; Fukuoka et al. 2008). The almost complete abolition of response to 
bradykinin in colonic afferents suggests that Nav1.9 and B2 are very closely co-
expressed. The intestinal data relate to a mixed population of spinal and vagal 
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afferents. The decrease in response to bradykinin was significant but not as great in 
magnitude as the purely spinal population of the colonic nerve. This suggests that B2 
may be expressed in a wider population of nerves some of whom do not express 
Nav1.9. A co-expression study in somatic afferents showed that 63% of B2 expressing 
neurons co-express Nav1.9 (Amaya et al. 2006). Thus, as an explanation for the 
findings presented here, I postulate that nearly all B2 expressing spinal visceral 
afferents express Nav1.9 with a significant majority of B2 expressing vagal afferents 
co-expressing Nav1.9.  
 
3.5.3 The role of Nav1.9 in the activation of visceral afferents by capsaicin 
The data generated provide evidence for an important role for Nav1.9 in the 
response of visceral afferents to capsaicin. The response of colonic and intestinal 
afferents to capsaicin was reduced by approximately 50% in Nav1.9 -/- mice. In 
contrast to the response to bradykinin, the attenuation in response to capsaicin was 
consistent between intestinal and colonic afferents.  
 
These data are consistent with that from a behavioural study in somatic afferents 
investigating the immediate paw licking response caused by intraplantar injection of 
capsaicin. Amaya et al investigated this response in Nav1.9 +/+ and -/- mice. Injection 
of 2.5 µg capsaicin caused an immediate response in both groups of mice but the 
response in Nav1.9 -/- mice was reduced by nearly 50% (Amaya et al. 2006). In 
addition, Nav1.9 -/- mice also exhibited significantly reduced mechanical 
hypersensitivity. Data from this behavioural study are thus consistent with the 
findings reported here with regards to the magnitude of the effect of eliminating 
Nav1.9. 
 
Capsaicin is the agonist for TRPV1, a cation channel (Caterina et al. 1997). Binding of 
capsaicin to TRPV1 leads to inflow of calcium ions with consequent changes of the 
membrane potential. This may lead to a generator potential which can be a 
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precursor to an action potential. In addition, TRPV1 mediated neuropeptide release 
may exert GPCR mediated modulation of afferent activity (Luo et al. 2013). Studies 
of back labelled visceral DRG showed that approximately 82% of spinal, 50% of pelvic 
and 32% of vagal DRG express TRPV1 (Robinson et al. 2004; Brierley et al. 2005a; Tan 
et al. 2009). Due to the lack of studies investigating he expression of Nav1.9 in 
visceral afferents, there are no data on the co-expression of Nav1.9 and TRPV1. 
However, somatic co-expression studies reveal that approximately 55% of TRPV1 
expressing neurons co-express Nav1.9 (Amaya et al. 2000; Amaya et al. 2006). It is 
intriguing that despite evidence from back labelled visceral DRG showing significantly 
more TRPV1 positive neurons in spinal vs. vagal afferents, the reduction in response 
in colonic and intestinal afferents was similar in the current studies. Intestinal nerves 
contain a mixed population of vagal and spinal afferents. What is not known is the 
relative contribution of each population to the overall nerve bundle. There is some 
evidence that the density of Nav1.9 positive afferents is significantly higher in spinal 
vs. vagal afferents (Peeters et al. 2006). It is tempting to speculate that as the 
proportion of afferents expressing TRPV1 and Nav1.9 is lower in the vagal pathway, 
the percentage of afferents which express both receptors is similar to that in the 
spinal pathway. This is a potential explanation for the similar reduction in response 
of intestinal and colonic afferents to capsaicin in Nav1.9 -/- mice.  
 
While it is evident that activation of TRPV1 is sufficient to cause action potential 
generation independently of Nav1.9, the data presented here clearly demonstrate a 
contribution by Nav1.9 to visceral afferent excitability. Based on its low activation 
threshold and the voltage dependant nature of its activation, it is likely that Nav1.9 
acts as an amplifier of the generator potential caused by activation of TRPV1. The 
loss of this amplifying role in Nav1.9 -/- mice leads to a reduced response of afferents 
to stimulation by capsaicin.  
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3.5.4 The role of Nav1.9 in the activation of colonic afferents by acetic acid 
The data generated demonstrate a complex relationship between Nav1.9 and acetic 
acid activation of visceral afferents. Taken as peak responses, there was no 
significant difference between afferents from Nav1.9 +/+ and -/- mice at all 
concentrations tested. However, this obscures nuances within the responses. The 
0.01% did not activate afferents from either genotype. At the 0.1% concentration, 
the peak response was lower in Nav1.9 -/- mice but this was not significant. The 
complete profile of the response was, however, strongly significant (p<0.01) 
resulting from the total number of action potentials activated by the acetic acid 
being significantly lower in Nav1.9 -/- mice. The 0.3% dose elicited a unique response 
in both genotypes. The afferents increased their firing rate to reach a peak response 
within approximately 200 seconds before returning to baseline activity. In the 
majority of afferents, the discharge rate increased again to reach a second, smaller 
peak. Both peaks were lower in the Nav1.9 -/- mice but the difference did not reach 
significance. The time from administration of acetic acid to the second peak was, 
however, significantly longer in Nav1.9 -/- mice. In addition, the combined response 
profile was significantly different between the genotypes reflecting the lower 
number of action potentials generated in Nav1.9 -/- mice. Interestingly, at the top 
dose of 1%, the peak response was higher in Nav1.9 -/- mice but this was not 
significant. In addition, the peak was reached within 30 seconds followed by total 
cessation of nerve activity (spontaneously and in response to mechanical 
stimulation) for at least one hour.  
 
The findings reported here are in contrast to those in the literature. A behavioural 
study conducted in Nav1.9 +/+ and -/- mice demonstrated a significant increase in 
pain behaviour in Nav1.9 -/- mice (Leo et al. 2010). The authors injected 1% acetic 
acid intraperitoneally and then counted the number of abdominal contractions 
between 5 and 20 minutes later. The authors counted twice the number of writhes 
in Nav1.9 -/- compared to +/+ mice. This is counterintuitive, as loss of Nav1.9 has 
been shown to have a protective effect on pain behaviour after application of 
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algogenic mediators. Intraperitoneal injection of acetic acid can be criticised as a 
non-natural inflammatory stimulus. In addition, it causes activation of visceral and 
somatic afferents which will both contribute to pain behaviour. Indeed, the authors 
state that a number of ‘incorrectly’ injected mice were excluded from their analysis. 
At the top dose in my study (1%), the response of visceral splanchnic afferents was 
not significantly higher in Nav1.9 -/- as compared to +/+ mice. Although the 
concentration of acetic acid at addition to the recording chamber was 1%, there was 
inevitably some dilution as it mixed with the Krebs buffer in the chamber. Thus, it is 
likely that the afferents in the current study were not exposed to the full effect of 1% 
acetic acid. Nevertheless, even this reduced dose caused a great increase in afferent 
activation which was difficult to fully capture and lasted for less than 2 minutes 
followed by complete cessation of afferent activity. This is in contrast with the 
behavioural study in which the authors monitored pain behaviour 5 - 20 minutes 
after injection of the acetic acid.  
 
A second behavioural study found no role for Nav1.9 on the response of visceral 
afferents to acetic acid (Ritter et al. 2009). The authors infused the bladder with 
0.25% acetic acid and recorded the maximal infused and voided volumes as well as 
bladder pressures in Nav1.9 +/+ and -/- mice. The results of this study are in 
agreement with data presented here where there was no difference in the peak 
response of colonic splanchnic afferents between Nav1.9 +/+ and -/- mice. The 
difference in the results between the two behavioural studies maybe due to the 
different concentrations used (as suggested by my data) or due to the relative 
contribution of Nav1.9 to each signalling system (Nav1.9 has been shown to be rarely 
expressed in non-inflamed bladder afferents (Black et al. 2003)). 
 
The mechanism of action of acetic acid is not fully understood. It is possible that 
acetic acid exerts its effects by activating membrane receptors, for example TRPV1 
or ASIC may be activated by the low pH. Indeed, there is evidence that antagonism 
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of TRPV1 reduces the visceromotor response to colorectal distension caused by 
acetic acid infusion (Wiskur et al. 2010). From the current data it appears that acetic 
acid acts on visceral afferents via more than one mechanism. At lower doses, the 
activation of afferents seems to be partially via a Nav1.9 pathway as there was a non-
significant decrease in the peak response in Nav1.9 -/- mice. The 0.3% dose produced 
a biphasic response. The first peak was reached quickly and the afferent activity 
returned to baseline. The second phase of the response reached a peak which was 
lower than the first in mice from both genotypes. This peak was lower and took 
significantly longer in Nav1.9 -/- mice. It is tempting to speculate that this second 
phase may be due to neuropeptide release by the afferents which activates second 
messenger pathways linked to Nav1.9. The top dose of acetic acid caused a large and 
very brief increase in activity which was not significantly higher in Nav1.9 -/- mice. 
That this top dose seems to have an opposite effect on the afferents as compared to 
the lower doses could be due to the fact that such a strong stimulus bypasses the 
threshold setting properties of Nav1.9 and may make other Nav channels more 
available and indeed activate other ion channels. In addition, acetic acid is an 
artificial stimulus that is not normally encountered by afferents and so its value as a 
disease model is questionable.  
 
3.5.5 The role of Nav1.9 in the activation of colonic afferents by human 
inflammatory supernatants 
This study is the first to demonstrate activation of visceral afferents by human 
inflammatory supernatants from diseased tissue that is the cause of pain. The data 
generated provide evidence for an important role for Nav1.9 in the response of 
visceral afferents to the inflammatory supernatant. The response of colonic afferents 
was reduced by nearly 50% in Nav1.9 -/- mice. The data also demonstrate that 
visceral afferents can be activated by supernatant from non-inflamed tissue but that 
this activation is significantly lower than that by supernatant from inflamed tissue. 
This allows the use of the non-inflamed supernatant as a control. The use of the 
same supernatant on nerves from Nav1.9 +/+ and Nav1.9 -/- mice acted as an internal 
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control. While this was only possible in 2 supernatants, this difference in activation 
of Nav1.9 -/-  and Nav1.9 +/+ nerves in both cases provides another layer of evidence 
supporting a role for Nav1.9 in the response of the nerve to the inflammatory stimuli 
contained within the supernatants.  
While no group has investigated the activation of visceral afferents by human 
‘overtly’ inflammatory supernatants, two studies have been published that 
demonstrate activation of extrinsic and enteric visceral afferents by supernatants 
generated from biopsy samples of patients suffering from IBS (Barbara et al. 2007; 
Buhner et al. 2009). In addition, another group have demonstrated the development 
of mechanical hyperalgesia to colorectal distension in mice whose colon were 
instilled with supernatant created from biopsy samples of IBS patients (Cenac et al. 
2007).  
 
While there are a number of studies measuring serum cytokine levels in patients 
suffering from acute appendicitis, none measured the cytokine levels in the appendix 
itself. Three groups have measured the local release of inflammatory mediators by 
analysing peritoneal fluid, either by aspirating it at the beginning of the operation or 
by instilling 0.9% saline and then aspirating 1 minute later (Rivera-Chavez et al. 2003; 
Dalal et al. 2005; Yamamoto et al. 2005). This method is unlikely to result in a 
supernatant whose contents are a true reflection of the cytokine content of the 
inflamed appendix. The groups tested for a range of cytokine including IL-1β, IL-6, IL-
8, GM-CSF and TNF-α. The cytokine levels measured by the groups were highly 
variable with a wide range for each cytokine, for example in one study the average 
IL-6 level was 3,910 pg/ml with the 25th and 75th percentiles stated as 869 and 
17,500 respectively (Rivera-Chavez et al. 2003). The variability between groups was 
also high with average levels for IL-8 reported as 35 pg/ml in one study and 1,416 
pg/ml in another (Rivera-Chavez et al. 2003; Dalal et al. 2005). Cytokines were not 
detected in every sample tested including in perforated or gangrenous appendicitis 
(Rivera-Chavez et al. 2003; Yamamoto et al. 2005). The cytokine levels detected in 
the current experiments reflected this variability. Although cytokine levels in 
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supernatant from inflamed tissue were higher than that from normal tissue, this did 
not reach significance. This is partly due to the inter-sample variability and small 
sample size but also due to the presence of moderate amount of some cytokines, 
e.g. IL-6, in the control tissue. In addition, the detection of very low levels of TNF-α in 
inflamed tissue was surprising considering its pro-inflammatory role. These findings 
may be related to the method used to produce the supernatant: during the 30 
minute incubation of the appendix in buffer, further cytokines are being released in 
both control and inflamed tissue. This may explain the relatively high level of some 
cytokines in non-inflamed tissue. Variation in the disease process may also account 
for the variability between samples. Unlike laboratory animals and off the shelf 
mediators, human disease samples are not uniform. Patients do not present at a 
similar time in the disease process and their immune system responses to the 
inflammatory process are highly variable. This is one of the features that plague 
clinical trials of compounds that have been successful in the laboratory. One of the 
solutions would be to increase the sample size to account for the natural variability 
in human disease.  
 
The white cell count of the patients who donated inflamed appendices were higher 
than those who donated normal appendices as would be expected based on their 
respective aetiologies (inflammatory process vs. cancer). The difference in ages is 
also a consequence of the disease aetiology. 
 
The colonic afferents tested produced a robust response to application of the 
inflammatory supernatants. The magnitudes of the responses were smaller than 
those after application of single mediators, e.g. bradykinin or capsaicin. This may be 
accounted for by two factors. First, all studies involving single mediators had a 20 ml 
volume of mediator applied to the recording chamber and this was sufficient to 
replace the chamber volume. The size of the appendices limited the volume of 
supernatant available with a range of 10 - 15 ml used. Secondly, more concentrated 
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supernatants are likely to have stimulated the afferents to a greater degree. The 
calculation of supernatant volume = 2.5 x appendix weight was used as a 
compromise between concentration of cytokines and volume of supernatant. An 
alternative would have been to combine supernatants from more than one patient 
to produce a more concentrated 20 ml of supernatant for use in each experiment. 
This, however, would have broken the link between an individual patient and the 
afferent experiment.  
 
Another finding of my study is the longer time period between addition of the 
supernatant and the beginning of the afferent response when compared to the 
single mediators. This may be a function of the smaller volume being diluted in the 
recording chamber but it may also be a reflection that most of the mediators in the 
supernatants signal via second messenger pathways to initiate action potentials. The 
significantly lower peak activation in Nav1.9 -/- mice suggests that Nav1.9 may have a 
role in the downstream signalling pathways of these mediators. 
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4 
The role of prostaglandins in 
afferent signalling 
 
4.1 Aims 
 
The aims of the experiments discussed in this chapter are:  
1. To investigate the role of Nav1.9 in the response of visceral afferents to 
prostaglandin E2  
2. To investigate the role of prostaglandins in the spontaneous activity of 
visceral afferents in Nav1.9 +/+ and -/- mice 
3. To investigate the role of prostaglandins in the response of visceral afferents 
to bradykinin in Nav1.9 +/+ and -/- mice 
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4.2 Specific rationale 
 
Prostaglandins are known to increase afferent activity in rodents. However, patch 
clamp data are conflicting with regards to the role of PGE2 on the Nav1.9 current 
with some authors demonstrating enhancement of the current while others failing to 
demonstrate an effect. PGE2 has also been shown to augment the response of 
visceral afferents to bradykinin. In view of the conflicting patch clamp data, I 
investigated whether this enhancement of bradykinin response occurs in the 
absence of Nav1.9. A further discussion of the rationale for the experiments in this 
chapter is outlined below. 
 
4.2.1 Cyclooxygenase pathway 
Cyclooxygenase (COX) mediates the conversion of arachidonic acid into 
prostaglandin H2 which is then converted to one of a number of prostanoids (Figure 
30). COX exists as 2 isoforms termed COX-1 and COX-2. Analogous to the bradykinin 
B1 and B2 receptors, COX-1 is constitutively expressed whereas COX-2 is induced by 
inflammation (Ricciotti and FitzGerald 2011). 
 
 
Figure 30 An outline of the cyclooxygenase (COX) pathway for metabolism of arachidonic acid. PGH2: 
prostaglandin H2. 
 
NSAIDs are non-selective blockers of COX-1 and COX-2 with consequent inhibition of 
prostaglandin synthesis. This leads to a reduction in inflammation and also has 
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analgesic effects. In addition to their pro-inflammatory roles, prostaglandins also 
have a physiological role in the GI, renal and cardiovascular systems (Ricciotti and 
FitzGerald 2011). Consequently, one of the side effects of NSAIDs is a change in the 
balance between the protective and damaging influences on the GI mucosa leading 
to ulceration and risk of significant haemorrhage. Other effects of COX blockade 
include cardiac and renal failure. This range of side effects stimulated the 
development of COX-2 specific blockers. While these drugs had lower GI side effects, 
their cardiovascular side effect profile led to their withdrawal. 
 
4.2.2 Role of prostaglandins in inflammation 
Prostaglandins exert their effects by activating GPCRs which have been named EP, 
DP, IP and FP for prostaglandin E2, D2, I2 and F2 respectively (Woodward et al. 2011). 
Some of these receptors (e.g. EP and DP) have a number of subtypes which couple to 
different messenger pathways. The stimulation of PKA and PKC production mediates 
voltage-gated sodium channel and TRPV1 function thus increasing sensory afferent 
excitability (Fitzgerald et al. 1999; Matsumoto et al. 2005). PGE2 is one of the most 
abundant prostaglandins and exhibits a variety of functions depending on the 
conditions: it is a mediator of many physiological functions e.g. immune responses 
and GI protection. During inflammation, it is significantly up regulated and plays a 
role in many of the constituents of the inflammatory response e.g. vasodilatation 
and pain (Ricciotti and FitzGerald 2011).  
 
Evidence for a role for prostaglandins in afferent activity is available from studies in 
somatic and visceral afferents. In an in vivo experiment, systemic administration of 
PGE2 significantly increased the activity of jejunal afferents (Haupt et al. 2000). In 
addition, application of a non-specific COX blocker, naproxen, reduces the intensity 
of spontaneous afferent activity (Maubach and Grundy 1999). Naproxen also blunts 
the response of visceral afferents to high dose bradykinin. This blunting of the 
response to bradykinin is reversed by the subsequent addition of PGE2. The afferent 
response to low dose bradykinin was not affected by naproxen. This suggests that 
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although bradykinin can activate visceral afferents independently of the COX 
pathway, products of this pathway are necessary for the full effect of bradykinin to 
be sensed by the afferents (Maubach and Grundy 1999). PGE2 also increases the 
number of DRG neurons that respond to bradykinin as well as the magnitude of the 
response in somatic and visceral afferents in the absence of COX blockade (Mense 
1981; Stucky et al. 1996; Brunsden and Grundy 1999). In addition, PGE2 sensitises the 
activity of TRPV1 on sensory neurons while blockade of COX attenuates the increase 
in visceral afferent activity due to application of histamine (Brunsden and Grundy 
1999; Zhang et al. 2008).  
 
4.2.3 Interplay between PGE2 and Nav1.9 
There is some evidence for a relationship between PGE2 and Nav1.9. Patch clamp 
studies have demonstrated an increase in Nav1.9 current after application of PGE2 
(Rush and Waxman 2004; Li and Schild 2007) while multiunit recordings of bladder 
afferents show that the increase in activity caused by instillation of PGE2 into the 
bladder is absent in Nav1.9 -/- mice (Ritter et al. 2009). Two behavioural studies have 
also investigated the relationship between Nav1.9 and PGE2 albeit in somatic 
afferents. Injection of PGE2 into the hind paw of mice produces mechanical allodynia 
to probing with von Frey hairs and thermal hyperalgesia during a hot plate test. In 
Nav1.9 -/- mice, the mechanical allodynia was attenuated while the thermal 
hyperalgesia was absent (Priest et al. 2005; Amaya et al. 2006). A parallel study in 
visceral afferents is lacking. Based on these somatic studies as well as patch clamp 
studies and extracellular multiunit recordings from visceral afferents in which COX 
blockade has been shown to blunt the response of visceral afferents to bradykinin, it 
is expected that prostaglandins play a significant role in the response of visceral 
afferents to bradykinin in both Nav1.9 -/- and +/+ mice. In addition, PGE2 is expected 
to have a direct stimulatory effect on visceral afferents which is reduced in Nav1.9 -/- 
mice.  
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4.3 Experimental protocols 
 
4.3.1 Prostaglandin E2 
The effect of PGE2 on afferent activity was investigated in colonic preparations only. 
A single application of 3 µM PGE2 was the only mediator applied to each preparation. 
 
4.3.2 Bradykinin in the absence of indomethacin 
The effect of bradykinin on afferent activity was investigated in indomethacin free 
colonic preparations. Consecutive applications of 0.3 µM, 1 µM and 3 µM were 
superfused 60 minutes apart. The nerve activity had returned to baseline before the 
next dose was applied.  
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4.4 Results 
 
4.4.1 Response to prostaglandin E2 
 
The response of colonic nerves to PGE2 was investigated by application of a single 
dose of 3 µM PGE2 in the presence of indomethacin. The peak responses were 
significantly lower in Nav1.9 -/- compared to +/+ mice (Nav1.9 +/+ 4.1 ± 1.0 Hz vs. 
Nav1.9 -/- 1.8 ± 0.3 Hz; n=6; p<0.05. Figure 31d). The overall responses were also 
significantly different (two-way ANOVA p<0.001. Figure 31c).  
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Figure 31 The effect of 3 µM PGE2 on colonic nerve activity. Representative raw trace recordings and 
response rate (mean frequency over 60 seconds) from (a) Nav1.9 +/+ and (b) Nav1.9 -/- mice. The 
arrows indicate the addition of PGE2. Below the raw trace, 2 second extracts are shown before and 
after the addition of PGE2. (c) Average profile of response (two-way ANOVA p<0.001). (d) Histogram 
comparing the peak response. * p < 0.05 
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4.4.2 Role of prostaglandins in spontaneous afferent activity  
 
In agreement with indomethacin-containing experiments, the baseline activity of 
Nav1.9 -/- colonic nerves was significantly lower than +/+ mice in indomethacin-free 
experiments (Nav1.9 +/+ 14.3 ± 4.2 vs. Nav1.9 -/- 2.8 ± 0.6 Hz; n=7; p<0.05. Figure 
32a). In addition, within each group, inclusion of indomethacin in the Krebs buffer 
significantly reduced baseline activity (Nav1.9 +/+: indomethacin-free 14.3 ± 4.2 vs. 
indomethacin-containing 3.1 ± 0.6 Hz; n=7-34; p<0.001. Nav1.9 -/-: indomethacin-
free 2.8 ± 0.6 vs. indomethacin-containing 1.1 ± 0.2 Hz; n=7-26; p<0.01. Figure 32b).  
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Figure 32 The role of indomethacin in baseline activity. (a) histogram comparing the baseline activity 
of colonic nerves in indomethacin-free preparations. (b) histogram comparing the baseline activity of 
colonic nerves in indomethacin-containing and indomethacin-free preparations. ** p < 0.01 *** p < 
0.001 
George Boundouki 
 
 
 117 
4.4.3 Role of prostaglandins in the response to bradykinin 
 
In agreement with experiments containing indomethacin, the response to bradykinin 
was significantly greater in Nav1.9 +/+ compared to -/- mice. However, in contrast 
with the indomethacin-containing experiments, the response was not eliminated in 
nerves from Nav1.9 -/- mice (0.3 µM: Nav1.9 +/+ 16.6 ± 4.1 vs. Nav1.9 -/- 5.6 ± 1.7 Hz; 
p<0.05. 1 µM: Nav1.9 +/+ 18.2 ± 4.0 vs. Nav1.9 -/- 6.4 ± 1.8 Hz; p=0.02. 3 µM: Nav1.9 
+/+ 20.2 ± 5.2 vs. Nav1.9 -/- 7.7 ± 1.3 Hz; p<0.05; n=7. Figure 33d). The overall 
response to 3 µM bradykinin was significantly different between Nav1.9 +/+ and -/- 
mice in indomethacin-free experiments (two-way ANOVA p<0.001. Figure 33c). The 
duration of the response was not significantly different between the Nav1.9 +/+ and -
/- mice but the initial reduction in activity after the peak was steeper in -/- mice 
(Figure 34). 
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Figure 33 The effect of bradykinin on colonic nerve activity in indomethacin-free preparations. 
Representative raw trace recordings and response rate (mean frequency over 60 seconds) from (a) 
Nav1.9 +/+ and (b) Nav1.9 -/- mice after addition of 3 µM bradykinin. The arrows indicate the addition 
of bradykinin. Below the raw trace, 2 second extracts are shown before and after the addition of 
bradykinin. (c) Average profile of response to 3 µM bradykinin (two-way ANOVA p<0.001). (d) 
Histogram comparing the peak response to three concentrations of bradykinin. * p < 0.05 
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Figure 34 The duration of the colonic nerve response to 3 µM bradykinin in indomethacin-free 
preparations. (a) time from bradykinin entering the bath to nerve activity rising above baseline 
(Nav1.9 +/+ 39.4 ± 6.9 vs. Nav1.9 -/- 51.7 ± 10.4 seconds; n=7; p=0.35). (b) time from bradykinin 
entering the bath to peak response (Nav1.9 +/+ 283.7 ± 19.4 vs. Nav1.9 -/- 190.4 ± 45.7 seconds; n=7; 
p=0.08). (c) time from peak response to 80% of the peak response (Nav1.9 +/+ 140.0 ± 34.5 vs. Nav1.9 
-/- 37.1 ± 15.6 seconds; n=7; p<0.05). (d) time from peak response to 50% of the peak response 
(Nav1.9 +/+ 458.0 ± 81.6 vs. Nav1.9 -/- 157.4 ± 59.6 seconds; n=7; p<0.05). (e) time from peak 
response to 20% of the peak response (Nav1.9 +/+ 1443.0 ± 224.2 vs. Nav1.9 -/- 961.0 ± 271.8 
seconds; n=7; p=0.20). (f) time from bradykinin entering the bath to nerve activity returning to 
baseline (Nav1.9 +/+ 2776.0 ± 387.8 vs. Nav1.9 -/- 2200.0 ± 309.4 seconds; n=5-6; p=0.27). * p < 0.05 
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4.5 Specific discussion 
 
4.5.1 The role of Nav1.9 in the activation of colonic afferents by 
Prostaglandin E2 
The data generated demonstrate an important role for Nav1.9 in the response of 
visceral afferents to PGE2. The peak response of colonic afferents to PGE2 was 
reduced by nearly 50% in Nav1.9 -/- mice.  
 
These data are consistent with findings from electrophysiological and behavioural 
studies. PGE2 has been shown to increase Nav1.9 current in patch clamp experiments 
(Rush and Waxman 2004; Li and Schild 2007). In addition, while two studies did not 
show an increase in afferent activity in response to PGE2, (Brunsden and Grundy 
1999; Maubach and Grundy 1999), a third study from the same group did (Haupt et 
al. 2000). One reason that may account for the difference between the three studies 
is that, in the two studies that did not find an effect of PGE2 on afferent activity, the 
mesentery was detached from the jejunum while in the third study this did not 
occur. Two behavioural studies have investigated the role of Nav1.9 in the response 
of somatic afferents to PGE2. Injection of PGE2 into the hind paw of mice produces 
mechanical allodynia to probing with von Frey hairs and thermal hyperalgesia during 
a hot plate test. In Nav1.9 -/- mice, the mechanical allodynia was attenuated while 
the thermal hyperalgesia was absent (Priest et al. 2005; Amaya et al. 2006). In 
addition, extracellular recordings of bladder afferents show that the increase in 
activity caused by instillation of PGE2 into the bladder is completely absent in Nav1.9 
-/- mice (Ritter et al. 2009).  
 
Prostaglandin E2 produces its effects by binding to GPCRs termed EP1-4 (Woodward 
et al. 2011). The effect of PGE2 on visceral afferent activity has been shown to be 
mainly mediated via EP1 (Haupt et al. 2000). Although the signalling pathways of EP1 
are not fully understood, it is known that EP1 couples to Gq which ultimately activates 
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PKC (Woodward et al. 2011). The Nav1.9 current has been shown to be up regulated 
via a number of second messenger pathways including PKC (Baker 2005). It is thus 
likely that the modulation of Nav1.9 current by PGE2 occurs via this EP1/PKC 
mechanism.  
 
4.5.2 The role of prostaglandins in the spontaneous activity of colonic 
afferents 
The data generated demonstrate that prostaglandins play a significant role in the 
spontaneous activity of colonic afferents. In the presence of indomethacin, a non-
specific COX blocker, spontaneous colonic afferent activity was reduced by 60 - 80% 
in both Nav1.9 +/+ and -/- mice. 
 
These data are consistent with that of Maubach and Grundy (1999) who 
demonstrated a near 60% reduction in spontaneous activity in jejunal mesenteric 
afferents after application of naproxen, a non-specific COX blocker. The effect of COX 
blockade on spontaneous afferent activity in Nav1.9 -/- has not been investigated 
before but patch clamp studies from both dorsal root and nodose ganglia have 
demonstrated an increase in Nav1.9 current upon application of PGE2 (Rush and 
Waxman 2004; Li and Schild 2007).  
 
It is unclear whether the higher level of spontaneous activity in the absence of COX 
blockade is due to the physiological prostanoid tone of the tissue which would have 
been present in vivo or whether this is a result of the dissection and transfer of 
tissue to the recording chamber with the inevitable ensuing inflammatory reaction. 
To exclude the influence of prostaglandins on the Nav1.9 current, indomethacin was 
added to the Krebs buffer for all preparations except where the role of COX blockade 
was under investigation. 
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4.5.3 The role of Nav1.9 and prostaglandins in the activation of colonic 
afferents by bradykinin 
The data generated demonstrate an important role for prostaglandins in the 
response of colonic afferents to bradykinin in both Nav1.9 +/+ and -/- mice. In 
indomethacin containing preparations, the current experiments show a 90% 
reduction in the peak response to bradykinin in Nav1.9 -/- mice. In the absence of 
COX blockade, the peak responses to bradykinin were reduced by approximately 
60% in Nav1.9 -/- mice.  
 
Maubach and Grundy (1999) have demonstrated a reduction in the bradykinin 
response in the presence of naproxen, a non-specific COX blocker. The subsequent 
addition of PGE2 restored the bradykinin response close to its pre naproxen levels. 
This effect was more evident at the higher concentrations of bradykinin (up to 
10µM). A study on rat DRG has shown that, in the absence of COX blockade, the 
presence of PGE2 significantly increases the proportion of DRG that are responsive to 
bradykinin (Stucky et al. 1996). Data from both studies suggest that PGE2 causes a 
leftward shift of the stimulus-response curve and that the major part of the response 
at the higher concentrations was dependant on prostaglandins. This is confirmed by 
data presented here. The stimulus-response curve was flattened in the presence of 
COX blockade but not in indomethacin free experiments. This was even more 
evident in experiments in Nav1.9 -/- mice where the bradykinin response is virtually 
abolished in the absence of prostaglandins but shows a clear stimulus-response 
pattern in the presence of prostaglandins.  
 
Bradykinin exerts its effects partly through PKC which is known to enhance the 
Nav1.9 current (Baker 2005; Leeb-Lundberg et al. 2005). In addition, one of the PGE2 
receptors, EP1, couples to Gq which activates the production of PKC (Woodward et al. 
2011). It is thus possible that the two pronged production of PKC causes an increase 
in the activation of visceral afferents in a synergistic way. An alternative is that PGE2 
acts to sensitise the afferents to stimulation by bradykinin. In a sense, the afferents 
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are primed by PGE2 and further activation by a second mediator causes an enhanced 
response compared to single mediator activation. While experiments presented here 
did not explore which of the prostaglandins were responsible for the enhanced 
response to bradykinin, data generated by other laboratories and discussed above 
suggest that PGE2 is a major candidate. It is interesting to note that while the effect 
of bradykinin on afferent activation is significantly reduced in Nav1.9 -/-, its 
combination with prostaglandins is not completely blocked by knockout of Nav1.9. 
This multi-pronged activation of afferents may also be conducted via other channels, 
e.g. TRPV1, which at high enough stimulation are able to change the membrane 
potential to overcome the lack of contribution of Nav1.9.  
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5  
The role of Nav1.9 in the response of 
visceral afferents to distension 
 
5.1 Aims 
 
The aims of the experiments discussed in this chapter are:  
1. To investigate the role of Nav1.9 in the response of visceral afferents to 
luminal distension of the gastrointestinal tract  
2. To investigate the role of prostaglandins in the response of visceral afferents 
to luminal distension in Nav1.9 +/+ and -/- mice 
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5.2 Specific rationale 
 
Due to the widespread expression of mechanosensitive channels on nociceptive 
afferents, it is probable that there is considerable co-expression between these 
channels and Nav1.9. Loss of Nav1.9 is likely to reduce the response of visceral 
afferents to mechanical stimulation due to its low activation threshold and 
contribution to resting membrane potential. Surprisingly, an in vivo study of Nav1.9   
-/- mice did not show a reduction in the visceromotor response to colorectal 
distension (Martinez and Melgar 2008). The experiments in this chapter investigated 
the effect that loss of Nav1.9 has on the response of visceral afferents to luminal 
distension in vitro.  
 
5.2.1 Classification of colonic mechanoreceptors  
Colonic distension is a recognised cause of visceral pain. It has been known for a long 
time that people suffering from both IBS and IBD have a reduced threshold to feeling 
pain caused by distension as well as an increased response at each distension 
pressure (Ritchie 1973; Farthing and Lennard-jones 1978). In rodents, the inflation of 
a balloon inserted via the anus has been used to induce visceral pain for many years. 
Inflation of the balloon induces contraction of the abdominal muscles, known as the 
visceromotor response, which is correlated with the intensity of the stimulus (Ness 
and Gebhart 1988). This model of visceral pain, as well as the application of 
mechanical stimuli (e.g. von Frey hairs or circumferential stretching of the colon) 
during electrophysiological recordings, has enabled the characterisation of 
mechanosensitive visceral afferents. 
 
In the rat, only 16% of pelvic afferents respond to colorectal distension. Two thirds 
of these fibres respond to an average pressure of 3 mmHg and were classified as low 
threshold mechanoreceptors while the rest respond to an average pressure of 33 
mmHg and were classified as high threshold receptors (Sengupta and Gebhart 1994). 
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Similar ratios of low to high threshold afferents are found in the splanchnic nerves of 
the cat colon (2:1) and rat stomach (3:1) (Blumberg et al. 1983; Ozaki and Gebhart 
2001). The response of the low threshold afferents is greater than the high threshold 
afferents at all distension pressures (Sengupta and Gebhart 1994; Ozaki and Gebhart 
2001).  
 
In addition to colorectal distension studies, investigation of the mechanoreceptors of 
the colon and rectum have been conducted using a flat sheet preparation (Lynn and 
Blackshaw 1999). This allows a number of stimuli to be applied to the colon (e.g. 
probing or circular stretch). Using this technique, five classes of mechanoreceptors 
have been identified in mice (Brierley et al. 2004). Three classes are common to the 
lumbar splanchnic and pelvic nerves. Each nerve also contains a 4th unique class of 
mechanoreceptors (Table 2). 
 
Nerve Class of afferent Prevalence Probing Mucosal 
stroking 
Circular 
stretch 
LSN Mucosal 4%    
 Muscular 10%    
 Serosal 36%    
 Mesenteric 50%    
      
PN Mucosal 23%    
 Muscular/Mucosal 23%    
 Muscular 21%    
 Serosal 33%    
Table 3 Classes of mouse mechanoreceptors and the stimuli that activate them. LSN lumbar 
splanchnic nerve, PN pelvic nerve 
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As can be seen in Table 2, the proportion of serosal afferents is consistent between 
the two groups. In the pelvic nerve, the other afferents are equally divided between 
the 3 classes of afferents whereas in the splanchnic nerve, mesenteric afferents 
account for half of the total. A significantly higher proportion of afferents are 
mucosal in the pelvic nerve possibly reflecting the necessary sensitivity of the lower 
part of the colon and of the rectum to the passage of faecal matter. Pelvic afferents 
are also more responsive to mechanical stimuli in that they respond at lower 
thresholds, to lower intensity stimuli and to a greater extent than splanchnic 
afferents (Brierley et al. 2004). A study which measured the visceromotor response 
to colorectal distension in mice using electromyogram recordings of the abdominal 
wall muscles concluded that the response is transmitted solely via the pelvic nerve 
(Kyloh et al. 2011). The results from that study concur with data showing that only 
10% of splanchnic afferents respond to circular stretch (Brierley et al. 2004). These 
studies highlight the possible specialisation of afferents depending on where they 
terminate both in the gut and the spinal cord.  
 
There is evidence from both rat and mouse that mechanoreceptors also respond to 
chemical mediators including bradykinin, ATP, capsaicin and an inflammatory soup 
containing bradykinin, PGE2, serotonin and histamine (Sengupta and Gebhart 1994; 
Su and Gebhart 1998; Brierley et al. 2005a; Brierley et al. 2005b). The response of 
rodent splanchnic afferents to distension is sensitised by the application of 
bradykinin alone or as part of the inflammatory soup (Su and Gebhart 1998; Brierley 
et al. 2005b). On the other hand, application of capsaicin causes desensitisation of 
the afferents to distension (Brierley et al. 2005a). No sensitisation or desensitisation 
is seen in pelvic afferents. These results, along with data confirming the 
responsiveness of colonic afferents to heat, highlight the polymodal nature of 
visceral afferents.  
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5.2.2 Mechanical transduction channels 
A number of channels have been implicated in the transduction of mechanical 
stimuli into action potentials. These include members of the transient receptor 
potential (TRP) and ASIC families (Brierley 2010). The effect of elimination of these 
channels on response to mechanical stimuli is considered in this section.  
 
TRPV1 is expressed on 50% of pelvic and 82% of splanchnic afferents (Robinson et al. 
2004; Brierley et al. 2005a). Deletion of TRPV1 reduces the response of pelvic 
muscular/mucosal afferents and leads to a decreased visceromotor response to 
colorectal distension (Jones et al. 2005). TRPV4 is expressed on around 60% of 
colonic afferents (Brierley et al. 2008). Knock-out of TRPV4 leads to decreased 
responses and increased thresholds of splanchnic serosal and mesenteric afferents 
as well as pelvic serosal afferents. This reduction in response translates into reduced 
abdominal electromyography in response to colorectal distension (Brierley et al. 
2008). In addition, application of a TRPV4 agonist in wild-type mice sensitised 
splanchnic and pelvic responses to mechanical stimulation (Brierley et al. 2008). 
TRPA1 is also expressed on over half of colonic afferents (Brierley et al. 2009). 
Mirroring TRPV4, knock-out of TRPA1 leads to reduced responses and increased 
mechanical thresholds of splanchnic serosal and mesenteric afferents as well as 
pelvic serosal afferent which also translates into reduced abdominal 
electromyography in response to colorectal distension. In addition, application of a 
TRPA1 agonist in wild-type mice sensitised splanchnic and pelvic responses to 
mechanical stimulation which was more pronounced in mice suffering from TNBS 
colitis (Brierley et al. 2009). While each channel seems to have an independent and 
significant role in visceral mechanotransduction, there is substantial interplay 
between channels as is highlighted by the lack of the usual mechanical 
desensitisation after capsaicin in TRPA1 -/- mice (Brierley et al. 2009). This 
interaction is enabled by the close co-expression of these channels with 97% of 
TRPA1 expressing DRG neurons also expressing TRPV1 (Story et al. 2003).  
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Amongst the ASICs, ASIC3 seems to play a role similar to the TRP channels. It is the 
most abundant of the ASICs and is expressed on 73% of retrogradely labelled colonic 
afferents (Hughes et al. 2007). Deletion of ASIC3 leads to significantly reduced 
responses in splanchnic serosal and mesenteric afferents as well as pelvic 
muscular/mucosal afferents (Jones et al. 2005; Page et al. 2005). In vivo, knock-out 
of ASIC3 leads to a reduced visceromotor response to colorectal distension (Jones et 
al. 2005). In contrast to ASIC3, other members of the ASIC family seem to have a 
dampening effect on the transduction of mechanical stimuli in the gut: elimination of 
these channels tends to increase the sensitivity of afferents. ASIC1 is expressed on 
30% of colonic afferents and its deletion increases the response of splanchnic 
mesenteric and serosal afferents to probing without altering their thresholds (Page 
et al. 2005; Hughes et al. 2007). ASIC2 is expressed on 47% of colonic afferents 
(Hughes et al. 2007). Its knock-out has variable effects depending on the class of 
afferents: the response of serosal afferents was increased whereas mesenteric 
afferents were unaffected. The thresholds of neither class of afferents were 
influenced by deletion of ASIC2 (Page et al. 2005). The contrasting effect of 
elimination of ASICs suggests that rather than functioning as individual mechanically 
gated ion channels, they operate together and with other mechanotransducers to 
exert their effects (Brierley 2010).  
 
5.2.3 Colorectal distension and Nav1.9 
Because of the wide expression of TRPV1, TRPV4, TRPA1 and ASIC3, it is likely that 
there is considerable co-expression between these channels and Nav1.9. Indeed, 
over half of TRPV1 expressing neurons also express Nav1.9 (Amaya et al. 2000; 
Amaya et al. 2006; Padilla et al. 2007). Due to its low activation threshold and 
persistent, slow current, it is likely that loss of Nav1.9 reduces the response of 
visceral afferents to mechanical stimulation. Surprisingly, an in vivo study of Nav1.9 
knock-out mice did not show a reduction in the visceromotor response to colorectal 
distension to 60 mmHg (Martinez and Melgar 2008). The authors used the pressure 
difference between the pressure generator used to inflate the balloon and the 
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pressure transducer as a surrogate measure for the visceromotor response and did 
not make electromyographic recordings. To accurately investigate a possible role for 
Nav1.9 in the response of visceral afferents to distension of a segment of GI tract, I 
studied the electrophysiological output of the splanchnic nerves in Nav1.9 wild type 
and knockout mice during distension to 60 (intestine) or 80 mmHg (colon).  
 
5.3 Experimental protocols 
The segment of intestine or colon was distended by occluding the outflow cannula. 
Due to the laxity of intestinal tissue, the maximum intraluminal pressure that could 
be consistently achieved was 60 mmHg whereas pressures of 80 mmHg were 
achieved in colonic tissue.  
 
5.3.1 Colonic experiments 
Because of the low spontaneous activity of colonic nerves, ramp distension to 80 
mmHg was undertaken at the beginning of each recording to confirm the 
establishment of a recording.  
 
5.3.2 Intestinal experiments 
In a subset of the capsaicin experiments, ramp distension to 60 mmHg was 
undertaken at the beginning of the recording.  
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5.4 Results 
 
5.4.1 Response to intraluminal distension 
 
In intestinal nerves, there was a trend for a lower response in Nav1.9 -/- mice (at 20 
mmHg: Nav1.9 +/+ 47.3 ± 15.9 vs. Nav1.9 -/- 18.8 ± 5.7 Hz; n=5-6; p=0.15, at 40 
mmHg: Nav1.9 +/+ 68.3 ± 19.9 vs. Nav1.9 -/- 27.0 ± 10.3 Hz; n=5-6; p=0.12 and 60 
mmHg: Nav1.9 +/+ 82.4 ± 28.0 vs. Nav1.9 -/- 55.6 ± 19.0 Hz; n=5; p=0.45. Figure 35d). 
The overall response was significantly different between Nav1.9 +/+ and -/- mice 
(two-way ANOVA; p<0.001. Figure 35c). 
 
In colonic nerves, there was a significantly lower response in Nav1.9 -/- mice (at 20 
mmHg: Nav1.9 +/+ 2.1 ± 0.6 vs. Nav1.9 -/- 0.5 ± 0.2 Hz; n=17-26; p<0.05, at 40 mmHg: 
Nav1.9 +/+ 3.4 ± 1.1 vs. Nav1.9 -/- 0.8 ± 0.4 Hz; n=17-26; p=0.08, at 60 mmHg: Nav1.9 
+/+ 4.6 ± 0.9 vs. Nav1.9 -/- 1.5 ± 0.4 Hz; n=17-26; p<0.05 and at 80 mmHg: Nav1.9 +/+ 
5.3 ± 0.9 Hz vs. Nav1.9 -/- 1.8 ± 0.5 Hz; n=17-25; p<0.01. Figure 36d). The overall 
response was also significantly different between Nav1.9 +/+ and -/- mice (two-way 
ANOVA; p<0.001. Figure 36c). 
 
Single unit analysis of the response of colonic afferents to intraluminal distension 
revealed that a similar proportion of units from Nav1.9 +/+ and -/- mice responded to 
distension (Nav1.9 +/+ 24/36 (66.7%) vs. Nav1.9 -/- 11/17 (64.7%); n=5-6). Of those 
distension sensitive units from Nav1.9 -/- mice, the majority did not respond to 
application of 0.3µM bradykinin. This is contrast to the distension sensitive units 
from Nav1.9 +/+ mice where the majority also responded to bradykinin (Nav1.9 +/+ 
2/24 (8.3%) vs. Nav1.9 -/- 9/11 (81.8%); n=5-6). 
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Figure 35 The effect of intraluminal distension to 60 mmHg on intestinal nerve activity. 
Representative raw trace recordings and response rate (mean frequency over 60 seconds) from (a) 
Nav1.9 +/+ and (b) Nav1.9 -/- mice. (c) Average profile of response (two-way ANOVA p<0.001). (d) 
Histogram comparing the responses at 20, 40 and 60 mmHg. 
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Figure 36 The effect of intraluminal distension to 80 mmHg on colonic nerve activity. Representative 
raw trace recordings and response rate (mean frequency over 60 seconds) from (a) Nav1.9 +/+ and (b) 
Nav1.9 -/- mice. (c) Average profile of response (two-way ANOVA p<0.001). (d) Histogram comparing 
the response at 20, 40, 60 and 80 mmHg. * p < 0.05 ** p < 0.01 
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5.4.2 Role of prostaglandins in the response to intraluminal distension 
 
There was a trend for a lower response of Nav1.9 -/- colonic nerves to intraluminal 
distension to 80 mmHg as compared to Nav1.9 +/+ in indomethacin-free 
experiments (at 80 mmHg Nav1.9 +/+ 20.4 ± 4.2 vs. Nav1.9 -/- 9.9 ± 3.3 Hz; n=7; 
p=0.07. Figure 37d). The overall responses were significantly different (two-way 
ANOVA p<0.001. Figure 37c). In addition, the distension responses were significantly 
higher in indomethacin-free compared to indomethacin-containing experiments 
(two-way ANOVA: Nav1.9 +/+ p<0.001; Nav1.9 -/- p<0.001. Figure 38).  
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Figure 37 The effect of intraluminal distension to 80 mmHg on colonic nerve activity in 
indomethacin-free preparations. Representative raw trace recordings and response rate (mean 
frequency over 60 seconds) from (a) Nav1.9 +/+ and (b) Nav1.9 -/- mice. (c) Average profile of 
response (two-way ANOVA p<0.001). (d) Histogram comparing the response at 80 mmHg. 
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Figure 38 The role of indomethacin in the response of colonic nerves to intraluminal distension in 
(a) Nav1.9 +/+ (two-way ANOVA p<0.001) and (b) Nav1.9 -/- (two-way ANOVA p<0.001) mice. 
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5.5 Specific discussion 
 
5.5.1 The role of Nav1.9 in the activation of visceral afferents by distension 
The data generated demonstrate an important role for Nav1.9 in the response of 
visceral afferents to intraluminal distension. The overall response of splanchnic 
afferents was significantly attenuated in Nav1.9 -/- compared to +/+ mice. It was 
approximately 75% lower at 20 and 40 mmHg and 65% lower at 60 and 80 mmHg. 
The overall response of intestinal afferents was also significantly attenuated in 
Nav1.9 -/- compared to +/+ mice albeit with smaller differences between the 
genotype. It was approximately 60% lower at 20 and 40 mmHg and 30% lower at 60 
mmHg. Single unit analysis of the response of colonic afferents to intraluminal 
distension revealed that a similar proportion of units from Nav1.9 +/+ and -/- mice 
responded to distension. The vast majority of these distension sensitive units from 
Nav1.9 +/+ mice also responded to application of bradykinin whereas only a small 
minority of units from Nav1.9 -/- mice did so. 
 
These findings are in contrast to those in the literature. A behavioural study 
conducted in Nav1.9 +/+ and -/- mice found no difference in the visceromotor 
response to colorectal distension (Martinez and Melgar 2008). The authors inserted 
a 2 cm long balloon 5 mm from the anus, inflated it to 60 mmHg and measured the 
consequent visceromotor response. No difference was detected between Nav1.9 -/- 
and +/+ mice. A possible explanation of this contradiction is provided by a study into 
the pathways activated by colorectal distension (Kyloh et al. 2011). The authors 
inserted an 8 mm balloon 4 - 7 mm from the anus, inflated it to 100 mmHg and 
obtained EMG recordings from the abdominal wall muscles. The authors then made 
sequential lesions in the splanchnic and pelvic afferent pathways and demonstrated 
that the whole of the colorectal distension response is transmitted via pelvic 
afferents. As my recordings are in splanchnic afferents, they are not expected to be a 
major contributor to the colorectal distension response measured by Martinez and 
Melgar (2008). It is thus possible that knockout of Nav1.9 has different effects on the 
George Boundouki 
 
 
 138 
two colonic afferent populations, splanchnic and pelvic: there is no change in the 
response of pelvic afferents whereas the response of splanchnic afferents is 
significantly reduced. 
The main mechanotransduction channels in visceral afferents are TRPV1, TRPV4, 
TRPA1 and ASIC3. Studies of back labelled visceral DRG showed that approximately 
82% of spinal, 50% of pelvic and 32% of vagal DRG express TRPV1 (Robinson et al. 
2004; Brierley et al. 2005a; Tan et al. 2009). In addition, over half of colonic afferents 
express TRPV4, TRPA1 and ASIC3 (Hughes et al. 2007; Brierley et al. 2008; Cenac et 
al. 2008; Brierley et al. 2009). As these receptors are expressed on a large proportion 
of visceral afferents, it is likely that many afferents will express a number of these 
channels. In fact, data from back labelled rat stomach afferents showed that 80% of 
TRPA1 expressing NG and DRG also express TRPV1 (Kondo et al. 2009). Due to the 
lack of studies investigating he expression of Nav1.9 in visceral afferents, there are 
no data on the co-expression of Nav1.9 and these channels. Data from the somatic 
system reveal that approximately 55% of TRPV1 expressing neurons co-express 
Nav1.9 (Amaya et al. 2000; Amaya et al. 2006). It is thus not unreasonable to 
postulate that there is close co-expression of Nav1.9 and these mechanotransducers.  
 
Intestinal nerves contain a mixed population of vagal and spinal afferents but the 
proportion of each population is not known. Vagal afferents are known to have 
lower mechanical thresholds in contrast to spinal and pelvic afferents (Knowles and 
Aziz 2009). The data presented here showed a significant attenuation of the 
mechanical responses across both vagal and spinal pathways. The nature of multi-
unit recordings did not allow the investigation of the role of Nav1.9 on separate 
populations of low and high threshold afferents.  
 
While Nav1.9 is not a transducer of mechanical stimuli, data presented here clearly 
demonstrate a role for Nav1.9 in the mechanical responsiveness of visceral afferents. 
This is likely to be a result of the biophysical properties exhibited by Nav1.9. Lack of 
George Boundouki 
 
 
 139 
the Nav1.9 current means that a stronger stimulus is needed to raise the membrane 
potential to the threshold required for action potential generation. Thus, Nav1.9 acts 
as an amplifier of other stimuli.  
 
5.5.2 The role of Nav1.9 and prostaglandins in the activation of colonic 
afferents by distension 
The data generated demonstrate an important role for prostaglandins in the 
response of colonic afferents to intraluminal distension in both Nav1.9 +/+ and -/- 
mice. There is an approximately 75% attenuation of the response at 80 mmHg in the 
absence of indomethacin, a non-specific COX blocker, across both genotypes.  
 
It is known that TRPV1 and TRPV4 currents are modulated via PKC (Vellani et al. 
2001; Alessandri-Haber et al. 2006). In the absence of indomethacin, tissue 
prostaglandins bind to their GPCRs which lead to the formation of PKC amongst 
other messengers. Thus it is likely, that these endogenous prostaglandins sensitise 
the afferents to mechanical transduction via PKC. In a similar manner to the 
synergistic activation of afferents by bradykinin and prostaglandins, while the 
response of visceral afferent to intraluminal distension is significantly reduced in 
Nav1.9 -/-, the combination of endogenous prostaglandins and distension is not 
completely blocked by knockout of Nav1.9. 
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6  
Discussion  
 
The data presented here demonstrate an essential role for Nav1.9 in the activation of 
visceral afferents by chemical and mechanical stimuli as well as a human 
inflammatory supernatant.  
 
6.1 Methodological considerations 
To investigate whether Nav1.9 plays a role in the response of visceral afferents to 
various stimuli, a colony of global Nav1.9 knockout mice was used which raises the 
possibility of compensation for this loss by other sodium channels. This is very 
unlikely. Nav1.9 expresses a unique slow, persistent tetrodotoxin-resistant current. 
No other voltage-gated sodium channel is able to express this current. In addition, 
there is no appreciable change in the expression or current of the other sodium 
channels in Nav1.9 -/- mice (Priest et al. 2005; Amaya et al. 2006). Nevertheless, an 
alternative would have been to use either a conditional knockout colony or siRNA to 
eliminate Nav1.9 from the tissue of interest. Both of these techniques require 
specific technical skills which are not available in our laboratory.  
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Data were acquired using an extracellular multiunit recording protocol which 
allowed measurement of the overall response in all classes of afferents that were 
activated by each test stimulus. An alternative would have been to make single unit 
recordings as described by the Blackshaw laboratory (Lynn and Blackshaw 1999). An 
advantage of the Blackshaw technique is that it allows detailed information about 
the effect of a stimulus on a single neuronal unit to be investigated, e.g. if the overall 
response to a mediator is decreased then the technique would permit the 
investigation into whether all units responded at a lower level or whether some units 
responded at the ‘normal’ level while others did not respond at all. This technique 
takes considerably longer to acquire the recordings with consequent degradation of 
tissue. In addition, technical issues such as establishing an adequate seal around the 
brass rods and damage to the tissue by repeated probing are potential 
disadvantages of the technique. The main advantage of extracellular multiunit 
recordings is that they provide a more representative model for the afferent input to 
the spinal cord. An alternative to both techniques would have been to use patch 
clamp studies. As the aim of the study was to investigate the role of Nav1.9 at the 
afferent terminal, the use of patch clamp studies would not have been appropriate.  
 
Other groups have shown that PGE2 increases the Nav1.9 current (Rush and Waxman 
2004; Li and Schild 2007). To prevent the response of visceral afferents to mediators, 
e.g. bradykinin or capsaicin, being ‘influenced’ by the presence of prostaglandins, 
indomethacin was added to the Krebs buffer in all experiments other than those 
investigating the role of prostaglandins. As can be seen from the results, 
prostaglandins act to sensitise the afferents to both chemical and mechanical 
stimuli. What is not clear is whether the prostaglandins present in preparations 
without indomethacin would have been present in vivo or whether they are a 
function of the inevitable degradation of tissue that occurs in the course of in vitro 
experiments. In a similar fashion, the effects of a number of mediators, e.g. 
bradykinin and PGE2, have been shown to be partly associated with muscle 
contraction (Floyd et al. 1977; Haupt et al. 2000). To avoid the ‘interference’ that 
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both these and spontaneous muscle contractions would cause to the afferent 
discharge, atropine and nifedipine were added to the Krebs buffer in all experiments. 
The intraluminal pressure was continuously monitored and confirmed the lack of 
smooth muscle contraction throughout the experiments including after addition of 
the mediators of interest. In addition, no contractions were visible during the 
experiments. 
 
6.2 Summary of results 
Nav1.9 has been shown to play an important part in visceral afferent signalling. The 
elimination of Nav1.9 significantly reduces spontaneous afferent activity in both 
colon and intestine. This is probably because Nav1.9 is activated at potentials close 
to the resting membrane potential. When this current is present, it raises the 
membrane potential closer to the action potential threshold thus allowing more 
afferents to generate action potentials. Nav1.9 has not been thought to play a role in 
the response of visceral afferents to mechanical stimulation in the absence of tissue 
inflammation (Martinez and Melgar 2008). Data presented here demonstrate clear 
attenuation of the distension response in Nav1.9 -/- mice. An explanation for the 
contradiction is the different populations of afferents studied as there is evidence 
that the colorectal distension response is mediated via the pelvic pathway whereas 
the current recordings were of the splanchnic pathway (Kyloh et al. 2011).  
 
The response of colonic and intestinal afferents to bradykinin and capsaicin is 
significantly attenuated in Nav1.9 -/- mice suggesting that Nav1.9 plays a key role in 
their signalling pathways. This finding is consistent with data from the somatic 
system in which Nav1.9 has been shown to have an important role in the primary 
response of afferents as well as the development of hypersensitivity to mechanical 
and thermal stimuli (Amaya et al. 2006). In addition, the response of colonic 
afferents to PGE2 is also significantly attenuated in Nav1.9 -/- mice which is 
consistent with data from the somatic and visceral systems (Priest et al. 2005; 
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Amaya et al. 2006; Ritter et al. 2009). The data also demonstrate that prostaglandins 
play important roles in afferent activity, both spontaneous, and in response to 
chemical and mechanical stimuli. This two-pronged stimulation of afferents is still 
significantly attenuated by loss of Nav1.9, albeit to a lesser degree. 
 
Acetic acid has been used for many years as a model for visceral pain. Recent data 
has been conflicting as to whether Nav1.9 plays a role in the response of visceral 
afferents to stimulation by acetic acid (Ritter et al. 2009; Leo et al. 2010). Data 
presented here demonstrate a complex interaction between acetic acid and Nav1.9. 
The peak change in response to various concentrations of acetic acid did not differ 
significantly between Nav1.9 -/- and +/+ mice. In contrast, the total number of action 
potentials recorded was different at concentrations of 0.1% and 0.3%. At the 0.3% 
dose, most nerve bundles produced a twin peaked response suggesting two 
mechanisms are responsible for the effect of acetic acid. The time to the second 
peak was significantly lower in Nav1.9 -/- mice indicating that the second response is 
conducted via a signalling pathway that involves Nav1.9. 
 
The activation of visceral afferents by human inflammatory supernatant is a new and 
exciting finding. I have demonstrated a clear difference in the level of activation of 
afferents between ‘normal’ and inflammatory human supernatants. In addition, the 
response of afferents to the inflammatory supernatants was significantly attenuated 
in Nav1.9 -/- mice. This finding has great translational potential and should allow for 
the conduction of subsequent experiments to test human supernatants from a 
variety of inflammatory conditions.  
 
6.3 Nav1.9 in context 
To date, investigation of the role of Nav1.9 has focused on events at the DRG level or 
on behavioural studies using a knockout colony. This thesis is the first to explore the 
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role of Nav1.9 at the afferent terminal. Data presented here confirm a significant role 
for Nav1.9 in visceral afferent activity. Nav1.9 has been shown to have a role in the 
setting the rate of spontaneous activity as well as the response of the afferents to a 
host of chemical mediators whether applied in isolation or as part of a more 
physiological mixture. In addition, Nav1.9 has been shown to play a significant role in 
the response of the afferents to mechanical stimulation. The response to chemical 
stimuli was reduced by 50-90% in Nav1.9 knock out mice while the response to intra 
luminal distension was reduced by 30-75% depending on region of gut and 
distension pressure. Only the peak response to acetic acid was not different between 
Nav1.9 wild type and knock out mice. The fact that Nav1.9 has a role in the response 
of afferents to a variety of stimuli indicates that it is at the heart of signal 
transduction of afferents. It is likely that Nav1.9 is co-expressed with a number of 
receptors (e.g. B2) and ion channels (e.g. TRPV1). This allows the channel to impact a 
variety of signalling pathways. Indeed, it is likely that nearly all B2 expressing visceral 
afferents co-express Nav1.9 while the majority of TRPV1, TRPV4 and TRPA1 
expressing afferents co-express Nav1.9. Nav1.9 is also likely to have a role in second 
messenger pathways which would explain the difference in the response to the 
inflammatory human supernatant and the second response to 0.3% acetic. Evidence 
for the role of Nav1.9 as an amplifier of other stimuli is seen in the afferent response 
to intra-luminal distension. Nav1.9 is not a transducer of mechanical stimuli. But, as a 
result of its biophysical properties, the presence of Nav1.9 on an afferent produces a 
significantly higher response to a given distension pressure. Therefore, the role of 
Nav1.9 seems to be at the confluence of a variety of signalling pathways. This, along 
with its restricted distribution make it an ideal target for visceral specific analgesics. 
 
6.4 Further work 
The data presented demonstrate a significant role for Nav1.9 in the response of 
visceral afferents to chemical and mechanical stimuli. Time and resource permitting, 
the results of further experiments would have complemented the dataset and 
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allowed a more comprehensive understanding of the magnitude of the role of 
Nav1.9. Some these further experiments are outlined in this section.  
 
The experiments performed as part of this thesis investigated either splanchnic 
afferents in isolation or as part of a bundle with vagal afferents. The data showed 
that the magnitude of effect of Nav1.9 is different between the two pathways. 
Specific experiments investigating the vagal nerve in isolation as well as the pelvic 
nerve are necessary to enable a fuller understanding of the contribution of Nav1.9 to 
signalling of the whole of the GI tract. In addition, single unit studies would add more 
detail to the contribution of Nav1.9 to each afferent class.  
 
The data presented here was acquired in vitro. While this is an appropriate model in 
the initial investigation of a target, it is necessary to perform in vivo and behavioural 
studies to understand the effect that manipulation of this channel has on the 
response of the subject to the stimuli being studied. Furthermore, experiments in 
animals that have been subjected to a disease model, e.g. TNBS colitis, would 
provide further data on the effect that elimination of this channel may have in man.  
 
The obvious gap in our understanding of Nav1.9 is its expression on visceral 
afferents. There is an urgent need for immunohistochemical studies of retrogradely 
labelled visceral afferents which will allow us to better understand the distribution of 
Nav1.9 as well as its co-localisation with channels that are also involved in the 
afferent response to noxious stimuli. In addition to these retrograde labelling studies 
in rodents, experiments should be performed on human colonic tissue and 
associated nerves to provide an understanding of the potential translatability of the 
results from rodent to man.  
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An abstract at the recent meeting of the International Association for the Study of 
Pain highlighted a possible role for Nav1.9 in erythromelalgia in man (Zhang et al. 
2012). Two mutations of Nav1.9 were found in patients who described ongoing 
‘burning’, ‘pricking’ or ‘stinging’ pain. A search for Nav1.9 loss of function mutations 
amongst patients who have congenital insensitivity to pain should also be instituted. 
Should these be found, they would provide more evidence of a role for Nav1.9 in the 
pathogenesis of pain.  
 
6.5 Summary 
Data presented here highlight the hitherto under investigated role for Nav1.9 in 
visceral afferent signalling. The magnitude of effect that Nav1.9 has on the activation 
of afferents suggests that a number of signalling pathways converge on Nav1.9 
rather than Nav1.9 being one of many pathways that these mediators utilise to exert 
their effects. Nav1.9 has been shown to be involved in the response to stimuli which 
act via GPCRs and also through activation of ion channels. A thought provoking 
explanation is that Nav1.9 acts as an amplifier of these disparate signalling pathways. 
This would necessitate a fewer number of each receptor to be expressed on a 
particular afferent thus allowing ‘more room’ for expression of a variety of receptors 
on a single afferent. Thus it is the presence of Nav1.9 that allows afferents to be truly 
polymodal. Nav1.9 seems to have more significant effects on splanchnic rather than 
vagal afferents. Whether this is due to differing expression patterns or the inherent 
characteristics of the different pathways is not clear. Thus, a Nav1.9 blocker might be 
more effective on the splanchnic rather than the vagal afferents. Additionally, the 
data show that COX blockade enhances the effect of elimination of Nav1.9 on the 
response of afferents to noxious stimuli. Notwithstanding the side effects of non-
specific COX blockade, the data suggest that simultaneous blockade of Nav1.9 and 
COX could provide for a significant reduction in the activation of afferents by 
chemical and mechanical stimuli.  
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7  
Conclusion 
 
Using consistent methodology, this thesis has documented an important role for 
Nav1.9 in the response of visceral afferents to a range of chemical and mechanical 
stimuli. In addition, Nav1.9 has been shown to play a role in the spontaneous activity 
of visceral afferents. Most importantly, the activation of visceral afferents by human 
inflammatory supernatants was significantly attenuated in Nav1.9 -/- mice suggesting 
that blockade of this channel in man could provide analgesic effects that, due to its 
restricted peripheral distribution, would not be expected to be associated with the 
side effect profile of the current non-specific sodium channel blockers.  
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